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ABSTRACT

Kestler, Bri, Ph.D., University of South Alabama, December 2021. Role of internal
calcium stores in the KCa2.3 regulation of human uterine smooth muscle contractions.
Chair of Committee: Mark S. Taylor, Ph.D.
Minute-to-minute regulation of intercellular calcium concentrations is essential to
allow the uterus to phasically contract and relax in a manner required for delivery. A
specific class of calcium-activated potassium (KCa2.3) channels has been strongly
implicated in the negative feedback control of intracellular calcium levels.
Overexpression of KCa2.3 channels compromises labor by diminishing uterine
contractions. Pharmacologic positive modulation of KCa2.3 channels with the small
molecule cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-yl]amine
(CyPPA), increases the calcium sensitivity of KCa2.3 channels and promotes membrane
hyperpolarization through potassium efflux. Local coupling of plasma membrane
channels, such as TRP and KCa, and internal store release channels is required for
activation and regulates tone in multiple vessels. A similar relationship in human uterine
tissue is proposed based on preliminary studies suggesting internal calcium stores play a
role in KCa-dependent feedback. This study characterized spontaneous and CyPPA
augmented contractions and the role of internal stores in the KCa feedback control of
human myometrial contractions.
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Dual staining immunofluorescence allowed us to observe the location and
distribution of KCa2.3 and Ip3R channels in human myometrium. We found multiple
staining patterns of KCa2.3 channels, with a general shift from more punctated signal in
the non-pregnant tissue to that of diffuse staining with varying intensity within pregnant
tissue. IP3R signal in human myometrium was generally diffuse with specific areas of
clustering and was generally preserved between gestational states. Proximity of KCa2.33
and IP3Rs differed between samples with some having very distinct individual channel
signal and others showing convergence of signal, possibly due to colocalization.
Using isometric force myography, we found that spontaneous phasic contractions
of non-pregnant and pregnant human myometrial tissue varied considerably and were
significantly different between gestational groups. CyPPA suppressed contractions in
both gestational groups and was more effective at reducing amplitude in pregnant
samples. CyPPA reduced contractility in tissue depleted of internal calcium stores via
cyclopiazonic acid; indicating the relaxant effects of CyPPA do not rely on internal
calcium store release in an unstimulated environment. CyPPA was able to significantly
reduce contractility in the presence of oxytocin and had the ability to blunt oxytocin’s
pro-contractile mechanisms further supporting its potential as a tocolytic agent.
In all aspects of the study there was variability in response to agents proposing
functional architecture determines the specificity of tissue response. The inability of
oxytocin to increase contractility when CyPPA was present suggests the cellular
arrangement between internal store release channels and KCa2.3 play a role in the
negative feedback control of uterine contraction and offer new insights into the innate
variability of human uterine contractions.

xv

CHAPTER 1
INTRODUCTION

The United States has the highest rates of preterm birth in the industrial world.
Preterm birth is defined as delivery before 37 weeks gestation and is the leading cause of
newborn death.1–4 The annual cost from disability and number of years lost due to ill
health in preterm neonates is estimated at $26.2 billion a year in the United States.2 While
the use of medications to combat preterm labor, or tocolytic medications, are not directly
associated with a reduction in neonatal complications, the brief delay of birth allows for
administration of antenatal corticosteroids.5,6 Application of antenatal corticosteroids
decreases fetal complications such as respiratory distress syndrome, intraventricular
hemorrhage, and necrotizing enterocolitis.3,6 Over the past decade, survival rates have
improved for preterm neonates, but this has been due to advances in neonatal care rather
than improvements in prenatal care.3,4 Spontaneous preterm labor accounts for
approximately 70% of preterm births, with the remaining 30% accounting for medically
induced birth due to maternal or fetal complications.2 With one in ten children born
prematurely, and only ineffective and outdated medications available for treatment,
regulatory mechanisms of uterine contractions need to be studied for identification of
new pharmacologic targets.
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Effective uterine contractions require an increase in cytosolic calcium
concentration, with depolarization of uterine smooth muscle occurring via calcium entry
through voltage-gated calcium channels (VGCC).7–9 An efflux of potassium ions through
calcium-activated potassium channels (KCa) results in membrane potential
hyperpolarization, reduced cytosolic calcium, and smooth muscle relaxation.10–16 A
specific class of small conductance KCa channels (KCa2.3) has been strongly implicated
in this negative feedback control of uterine contractions.10,11,14,17–20 Overexpression of
KCa2.3 channels impedes uterine contractions through increased hyperpolarizing effects
and closure of VGCCs.12,21,22 Exploitation of KCa2.3 channels has surfaced as a new
hope for tocolytic therapy.18,19,21,23,24 Studies suggest enhancing calcium sensitivity of
KCa2.3 channels with the compound cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6methyl-pyrimidin-4-yl]amine (CyPPA) reduces the force of uterine contractions by
amplifying calcium-dependent feedback.25–27 Indeed, CyPPA treatment delays delivery in
preterm laboring mice.27
Calcium release from the sarcoplasmic reticulum (SR) leads to increased
intracellular calcium levels and muscle contraction.28–31 Preliminary studies suggest
internal store calcium release may be crucial for CyPPA suppression of uterine
contractions through KCa2.3 channel positive modulation. A role for internal calcium
stores may be similar to that described recently in vascular endothelium where close
proximity between inositol 1,4,5-triphosphate receptors (IP3Rs) and KCa2.3 channels
provides an intrinsic, tunable mechanism for calcium feedback.32–35 Uterine contractility
may be altered due to an increase in local calcium concentrations around KCa2.3
channels which intensifies hyperpolarization. A functional relationship could explain data
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from our laboratory pointing to a synergistic effect between IP3R agonists and CyPPA.
Assessing the link between internal calcium stores and KCa2.3 channels in human uterine
tissue would open new targets and strategies for tocolytic therapy. Therefore, this
proposal tests the HYPOTHESIS that internal calcium stores drive KCa2.3 feedback
suppression of human myometrial contractility.
AIM 1: Evaluate the expression and distribution of KCa2.3 and IP3R channels in human
myometrium.
AIM 2: Characterize spontaneous and augmented contractions of human uterine tissue.
AIM 3: Assess the role of the internal calcium stores in KCa2.3 modulation of human
uterine contractility.
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CHAPTER II
BACKGROUND

Uterine anatomy
The most superior aspect of the uterus is the fundus. Moving inferior, next is the
corpus, followed by the lower uterine segment and the isthmus, ending with the cervix.
The human uterus consists of three layers: an outer covering, the serosa; a middle
muscular layer, the myometrium; and an inner mucous membrane, the endometrium. The
serosal layer is a continuation of peritoneal epithelium and encloses almost the entire
uterus. The endometrium is a simple mucous membrane that is regulated by hormonal
secretion and is the site of fetal tissue implantation. The myometrium is the thickest layer
of the uterus and undergoes the most pregnancy associated changes. Within the
myometrium are an outer longitudinal muscle layer and an inner circular layer. The
muscle fiber bundles of the longitudinal muscle layer are oriented along the long axis of
the uterus, with individual myometrial smooth muscle cells (MSMCs) arranged in the
long axis of the bundle itself. The muscle cells of the circular layer are more diffusely
bundled, but generally arranged concentrically around the longitudinal axis of the uterus.
In humans, there is not clear delineation between muscle layers as there is in other animal
species.
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Figure 1. Anatomical regions and layers of the human uterus. The serosa is the outer
layer of the uterus that is continuous with the peritoneal epithelium. The myometrium is
the middle muscular layer composed of longitudinal and circular muscle fibers. The
endometrium is the inner mucosal membrane that includes the decidua during pregnancy.
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Uterine myocytes are spindle-shaped cells with a predominate nucleus, welldeveloped sarcoplasmic reticulum (SR), ample caveolae, and gap junctions between
neighboring cells.36 Myometrial growth during pregnancy is accomplished by an increase
in the number of MSMCs (hyperplasia), and to a lesser degree an increase in the size of
cells (hypertrophy). Myocytes increase from 2 – 20 microns in diameter and 50 – 1,000
microns in length during gestation.36 MSMCs are densely packed with myofilaments and
dense bodies, which together make up 80-90% of the cell. MSMC myofilaments are
either thin filaments 6-8 nm in diameter and composed mainly of globular actin, or thick
filaments 15-18 nm in diameter composed of myosin.37 There are six times more actin
containing filaments than myosin filaments in the myometrium. Actin filaments are
anchored to the cell and the cytoskeleton via dense bodies and dense bands. Dense bodies
are in the cytosol and bridge actin thin filaments together along the contractile plane.
They serve as anchors for actin filaments to exert force onto and bring polar cell
membranes together. Dense bands are associated with the peripheral membrane and form
structures around the circumference of the cell, allowing actin filaments to be tethered to
the cytoskeleton. Dense bands allow forces to be transmitted toward the peripheral
membrane during generation of mechanical tension.37

Hormonal regulation

Progesterone
While pregnancy is a complicated process that is still not fully understood it is
known to be partly controlled by two steroid hormones, progesterone and estrogen, and
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their metabolites. Progesterone is produced by the adrenal cortex and the ovaries during a
non-pregnant state, with a transition to the ovarian corpus luteum and the placenta during
pregnancy. Progesterone promotes a pro-pregnancy uterine phenotype mainly through
binding of progesterone to a nuclear progesterone receptor (nPR) that functions as an
intracellular ligand-activated transcription factor to mediate gene expression. The human
PR gene encodes for two isoforms: the full length PR-B and the truncated PR-A. PR-B is
the predominate isoform during early pregnancy and the largest mediator of
progesterone-induced transcriptional activity.38 The main genomic mechanism in which
PR-B promotes relaxation is through the suppression of contraction associated protein
(CAP) gene expression. Suppressed CAPs include uterotonic receptors, such as the
oxytocin (OT) receptor (OTR) and prostaglandin-F2a (PGF2a) receptor (FP), allowing
progesterone to diminish responsiveness to gestational hormones. Another is the gap
junction protein connexin-43 (Cx43), which unsuppressed allows for the propagation of
action potentials39 and direct intercellular communication between myometrial cells.40
PR-B inhibits myometrial inflammation and desensitizes myometrial tissue to
inflammatory stimuli through suppression of IL-11 expression41,42, impairment of the NFkB inflammatory pathway through upregulation of NF-kB inhibitors43,44, and inhibition
of TNF- and thrombin-induced weakening of the amnion membrane.45 PR-B also
stimulates myometrial relaxation by augmenting the cAMP/protein-kinase-A (PKA)
signaling pathway.46 Increased cAMP/PKA inhibits phospholipase C (PLC) from
elevating cytosolic Ca2+ levels, via stimulation by uterotonins, such as OT and PGF2a.46
In most species labor is triggered at term by a systemic decrease in progesterone,
though in humans’ progesterone levels remain elevated up until the final phase of labor.47
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One of the possible mechanisms for this functional progesterone withdrawal includes a
switch in the relative levels of PR isoforms.38,44 During early pregnancy, PR-B dominates
with PR-A levels being much lower creating a PR-A:PR-B ratio of approximately 1:2.38
Myometrial PR-A levels increase late in pregnancy causing a transition to PR-A
dominance and causing the PR-A:PR-B ratio to be 3:1 at time of delivery.38 PR-A is a
repressor of PR-B, especially when its levels dominate.38,44 PR-A promotes inflammation
by inhibiting the PR-B upregulation of NF-kB inhibitors, thereby increasing expression
of proinflammatory genes (e.g., PTGS2, IL8, IL1A, and PTX3).44 These findings support
the idea that progesterone promotes a relaxed myometrial state for most of pregnancy via
PR-B mediated genomic actions, which are inhibited late in pregnancy with an increased
expression of the PR-A isoform. Progesterone has also been shown to rapidly activate
intracellular signaling pathways through progestin membrane receptors. Progestin
membrane receptors activate inhibitory G proteins resulting in reduced cAMP production
and inhibition of adenylyl cyclase activity, as well activation of p38 mitogen-activated
protein kinase which causes phosphorylation of myosin light chain protein.48,49 These
findings suggest that progesterone could promote myometrial contractions during labor
through membrane receptor signaling. There is also evidence supporting progesterone’s
ability to trigger calcium release from internal stores through progestin membrane
receptors.50
Estrogen
In premenopausal women, the ovaries are the main source of estrogen with the
adrenal glands, adipose, hepatic and skin tissues also synthesizing small amounts. During
gestation, the corpus luteum and placenta become significant contributors to estrogen
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levels. The most common estrogens are estradiol, estriol, estrone, and estetrol. Estradiol
is the prevailing form during gestation, with a shift to estriol becoming the dominate
estrogen at term.51 Similar to progesterone, estrogen receptors (ERs) are intracellular
ligand-activated transcription factors and exist as two major subtypes, ERa and ERb.
Human ERs are derived from separate genes, have different ligand binding affinities, and
tissue distributions.52,53 Estrogen receptor complexes bind to estrogen response elements
(EREs) in genes and promote a contractile phenotype by encoding for and increasing
cellular sensitivity to CAPs and inflammatory cytokines. Estrogen’s additional genomic
mechanisms include stimulating the production of PGs by maternal and fetal tissues,
upregulating expression of OTR, and increasing gap junction formation to spread phasic
contractions.54–57
For most of pregnancy the human myometrium is refractory to estrogens, even
though circulating estrogen levels increase at around mid-gestation and continue to rise
gradually until birth.51 PR-B decreases uterine estrogen responsiveness by decreasing
ERa expression.58,59 ERa expression is high in non-pregnant tissue and low in nonlaboring term myometrium57, but increases with the onset of labor57,60, suggesting that
functional estrogen activation is mediated by increased ERa expression. ERa expression
positively correlates with the PR-A:PR-B expression ratio60 further supporting the theory
that functional progesterone withdrawal induces functional estrogen activation.61 ERb
mRNA is low in non-laboring and laboring myometrium57,60 and this isoform’s role in
parturition is being investigated further. Membrane G protein-coupled (GPCR) estrogen
receptors have been identified in myometrial tissue of rodents and humans with activation
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increasing depolarization, intracellular calcium levels, and myometrial contractile
responses to oxytocin. 62,63

Myometrial contraction physiology
The myometrium is a myogenic, phasically active smooth muscle that is
minimally active in the non-pregnant state and during most of gestation.36 Small regions
of the uterus develop low-amplitude contractions that are not sufficient to cause cervical
changes or initiate labor and these contractions slowly increase in frequency and strength
as pregnancy progresses. During parturition, uterine contractions become synchronous
with short durations and high amplitudes and involve the entire uterus.64 Active labor
contractions build until the fetus is delivered, but exact feedback mechanisms regulating
uterine contraction and relaxation are poorly understood. Myometrial electrical activity is
closely coupled to contractile activity so that the amplitude, frequency, and duration of
contractions correlate with the number of cells that are simultaneously active, their
electrical burst frequency, and the duration of the bursts.36,64
Myometrial excitation
The myometrium has the intrinsic ability to generate spontaneous electrical
activity without the requirement of extrinsic neural or hormonal stimuli, though these
factors can modulate them. Specialized pacemaker cells have been theorized as the
initiators of activity in the myometrium, but these cells have not been identified.
Different cells and channels have been evaluated on their ability to generate an action
potential.36 Spontaneous activity may arise from many myometrial muscle cells as
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initiation sites of electrical activity throughout the myometrium. For the uterus to contract
as an entire organ, rather separate multicellular regions, coordination of individual cell
activity is required. Depolarization of one cell is communicated to neighbors in a distinct
pattern, so the wave of depolarization proceeds in a direction to allow for delivery of the
fetus.64
Over the course of gestation, the myometrial tissue transitions from a state of low
intrinsic excitability, to one of high excitability that is vulnerable to stimulation.65 The
resting membrane potential of myometrial tissue varies depending upon gestational state.
Nonpregnant human myometrial membrane potential ranges from -40 to -60 mV, with
potentials becoming more negative during pregnancy (-60 mV), and returning to
approximately -45 mV at time of parturition.8,66–68 This change in resting membrane
potential allows for easier generation of spontaneous actions potentials and their
propagation through the myometrium in late pregnancy.
In the myometrium slow waves or gradual membrane depolarizations trigger
action potentials that lead to spontaneous contractions.36 Spike action potentials are the
predominate form in non-pregnant and early pregnancy, with Ca2+ the depolarizing and
K+ the repolarizing currents.36 During gestation action potentials become complex with a
plateau shape likely due to increased and prolonged Ca2+ influx and K+ channel
expression changes. Excitation is coupled between cells through gap junctions in the
plasma membrane composed mainly of Cx43. Gap junction expression and permeability
increases late in pregnancy which allows for faster propagation of action potentials.36
The myometrium expresses a plethora of different ion channels, and some have
been determined to be essential for excitability and contraction, while the roles of others
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are yet to be understood. An important contributor to cell excitability is the action of a
leak current. Leak currents are constitutively active and allow a flow of cations across a
cell membrane to depolarize the membrane and initiate action potential upstroke.69 The
myometrial leak current is Na+-dependent, tetrodotoxin-insensitive, and Gd3+-sensitive
and depolarizes the potential to the extent for activation of L-type voltage gated calcium
channels.69 The Na+-activated leak channel, non-selective (NALCN) channel allows
passage of Na+, Ca2+, K+, and Cs+ with decreased expression during mid-gestation and
increased expression during labor in mice.70 NALCN provides ~50% of the myometrial
leak current, as NALCN knockdown diminishes but does not complete abolish the leak
current in human MSMCs.69 Knockout of NALCN in mouse models reveals reduced
uterine excitability and increased incidence of abnormal labor, supporting its necessity
for successful delivery.70
Depolarization is caused by a rapid influx of calcium through these L-type
calcium channels.71,72 The membrane potential gradually repolarizes by efflux of
potassium ions, which reduces excitability and the duration of the action potential. The
frequency of action potential discharge, the duration of the action potential train, and total
number of cells activated determine the frequency, duration, and amplitude of uterine
contractions.68,73 Gap junctions are sites of propagation or conduction of action potentials
between cells, and are composed of a few to thousands of gap junction channels.73 Each
gap junction channel is constructed of connexin proteins, that creates a pore and links up
with another gap junction channel in an adjacent myocyte.73 This linkage of gap junctions
couple myocytes together and create an electrical and metabolic syncytium.7,9,73,74 Gap
junctions in the myometrium are composed primarily of Cx43.7,73 Coupling is poor
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during most of pregnancy, as gap junction numbers are low or absent, but during labor
gap junctions begin to occupy a significant percentage of myocyte plasma membrane.73–75
Junctions begin to form approximately one day prior to the onset of labor and increase in
number and size during delivery. Conditional ablation of connexin 43 in mouse MSMCs
resulted in delayed parturition, demonstrating the importance of this protein in cell-to-cell
coupling for action potential propagation and uterine contractions.42
Myometrial force generation
Consistent with other smooth muscle, human uterine smooth muscle relies on a
rise and fall of intracellular calcium concentration for contraction and relaxation. The rise
of intracellular calcium for myometrial contractions generally comes from two sources:
extracellular calcium influx through VGCC, and release of intracellular calcium from SR
stores.28–31,71,76 VGCCs, specifically the L-type calcium channels, provide the main route
for calcium entry into the myometrium8,9, and create a steady-state calcium entry during
sustained depolarization.72 Internal store channels, such as ryanodine (RyR) and inositol
1,4,5-triphosphate (IP3R) receptor channels, amplify intracellular calcium levels through
release of calcium from internal stores.
Contraction and relaxation of the myometrium is regulated by phosphorylation
and dephosphorylation of the regulatory chain of myosin, which in turn is regulated by
intracellular calcium concentrations. Phosphorylation of myosin is affected primarily by
an increase in intracellular calcium concentrations. Increased cytoplasmic free calcium
results in the binding of calcium to the calcium binding protein, calmodulin (CaM).66,77
After CaM has bound four calcium ions, it can bind to the CaM-binding domain
(CaMBD) on myosin light chain kinase (MLCK) resulting in activation of the enzyme.78
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MLCK specifically phosphorylates serine 19 on the regulatory myosin light chain,
resulting in activation of actomyosin MgATPase.76,78 Actin–myosin cross bridging
commences with movement of actin along myosin causing shortening of the muscle
fibers and the development of force.37,77,79
Calcium removal after contraction is necessary to induce relaxation and replenish
the SR. This is achieved by a variety of mechanisms, including the closure of plasma
membrane calcium channels, removal of calcium from the cytosol via plasma membrane
Ca-ATPase (PMCA) and the sodium calcium exchanger (NCX), and movement of
calcium back into the SR via the sarcoplasmic reticulum calcium ATPase
(SERCA).37,66,72 A reduction in myosin light chain kinase activity can occur due to
decreased intracellular calcium levels or via stimulation of the adenyl cyclase (AC)cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) pathway.37,80,81
Myosin light chain phosphatase (MLCP) dephosphorylates myosin, allowing for
detachment of actin from myosin cross bridging, and smooth muscle cell relaxation
(Figure 2).37,66 In the myometrium generation of global calcium transients is accompanied
by contractions. Rather than holding tone like vascular smooth muscle, when intracellular
calcium concentrations decrease, relaxation occurs in the myometrium. Also unlike
vascular smooth muscle, there is little evidence of force increasing without a change in
intracellular calcium.36

Potassium channels
Potassium efflux is responsible for maintaining the resting membrane potential and
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repolarizing membrane action potentials.11,82,83 Potassium efflux produces relaxation
through membrane hyperpolarization and impediment of calcium influx through VGCCs.
Early studies with potassium channel blockers demonstrated an increase in contraction
amplitude and duration due to prolongation of action potentials.84 Several types of
potassium channels have been identified in the myometrium with the most well studied
including the large-conductance calcium-activated potassium (BKCa) channels, ATPsensitive potassium (KATP) channels, voltage-gated potassium (KV) channels, and smallconductance calcium-activated potassium (SKCa, KCa2) channels.82,83,85
BKCa channels are the predominant potassium channel identified in myometrial
tissue.83 Their activity increases with membrane depolarization and/or increases in
intracellular calcium concentrations83,86, with activation primarily induced by voltage and
not calcium. Down regulation of BKCa channel transcripts occurs during pregnancy.87
KATP channels are ATP-sensitive inward rectifying potassium channels that regulate
cellular responses by coupling cell metabolism with membrane potential.88 The
potassium channel family Kir6 makes up the pore-forming component of the channel,
with ATP sensitivity, pharmacological properties, and trafficking regulated by a
sulfonylurea receptor.82,85 KATP channels are expressed at higher levels in non-pregnant
myometrium with a two to three fold downregulation in late gestation.83,88
KV channels are presumed to be responsible for repolarizing membrane action potentials
and regulating membrane potential.89 The KV4 subfamily has shown to play the most
predominant role in pregnant myometrium and generates a rapidly inactivating potassium
current in rat pregnant myometrium.82 Within the subfamily KV4.2 channel
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expression increased before labor, whereas KV4.1 and KV4.3 expression declined during
gestation, suggesting a possible hormonal regulation of channel expression.82

Figure 2. Diagram of uterine smooth muscle contractile mechanisms. A leaky Na+
current (demonstrated by NSCC) depolarizes the membrane potential enough to meet the
threshold potential and open voltage-gated, L-type calcium channels (VGCC).
This causes rapid Ca2+ influx, which binds to CaM and activates MLCK, leading to
phosphorylation of the myosin regulatory light chains, enabling interaction of myosin
with actin, cross-bridge cycling and force development. Membrane potential
depolarization activates KV channels and Ca2+ activates KCa channels, both causing K+
efflux and membrane repolarization, closing VGCC. Cytosolic Ca2+ levels continue to
decrease due to closure of membrane Ca2+ channels, removal of Ca2+ from the cytosol via
the PMCA and NCX, and movement of Ca2+ back into the SR via the SERCA. MLCP
dephosphorylates myosin, allowing for detachment of actin from myosin cross bridging,
and smooth muscle cell relaxation, until the next action potential. NSCC, nonselective
cation channel; VGCC, voltage gated Ca2+ channel; CaM, calmodulin; MLCK, myosin
light chain kinase; KV, voltage gated K+ channel; KCa, Ca2+-activated K+ channel;
PMCA, plasma membrane Ca2+-ATPase; NCX; Na+-Ca2+ exchanger; SR, sarcoplasmic
reticulum; SERCA; sarcoplasmic reticulum calcium ATPase; MLCP; myosin light chain
phosphatase.
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Small-conductance calcium-activated potassium channels
Bond et al. identified a relatively unstudied potassium channel as a major player
in the regulation of uterine contractility.12 KCa2.3, or SK3, is one of three subtypes of
small conductance calcium-activated potassium channels. A regulatory cassette with a
site-specific tetracycline/doxycycline-inhibitable transactivator protein that promoted
gene expression of KCa2.3 channel subunits, was inserted into mice. This doxycycline
(DOX)-sensitive genetic switch also allowed for titration of KCa2.3 expression levels
through administration of dietary doxycycline, which would suppress KCa2.3 expression.
Female mice that overexpressed KCa2.3 channels (SK3T/T) demonstrated normal mating
behavior, fertility, and carried pups to term. However, in seven of the ten litters, delivery
was protracted and some of the mothers and pups did not survive. Autopsy of mothers
that died during parturition revealed pups blocking the birthing canal. Eleven pregnant
mice that overexpressed KCa2.3 were given dietary doxycycline (SK3DOX) to normalize
KCa2.3 levels. In these mice delivery occurred in a normal fashion without injuries to
dams or pups.12 This study revealed KCa2.3 overexpression compromised labor and
identified KCa2.3 channels as an imperative regulator of myometrial contractility.
SKCa channels are present in non-excitable and excitable tissues, and their high
calcium sensitivity (0.3-0.5 µM), lends to its role in the regulation of signaling pathways
involving calcium. Three different isoforms of SKCa channels (KCa2.1-2.3, SK1-3)12 are
produced by three different genes (KCNN1-3)18,24, with channel isoforms sharing a high
overall structural homology.13 SKCa channels are six transmembrane channels composed
of four alpha subunits (Figure 3).14,15,24,90,91 The potassium selective filter and the pore
forming unit are located between the fifth and sixth transmembrane domain.82 Gating of
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SKCa channels is voltage-independent and relies exclusively on calcium binding to
constitutively associated CaM13–17,92, located at the CaMBD on the C-terminus of each
alpha subunit.13,14,24,90,92,93 The C-lobe of CaM mediates the constitutive interaction with
the CaMBD of SKCa channels.94 Calcium activation of SKCa channels is the result of
calcium binding to the two EF hands in the N-lobe of CaM.13,16,17,94 When calcium binds
to CaM, it undergoes a conformation change17,24,90, exposing residues that interact with
the CaMBD on an adjacent channel subunit.16,31,90 This shifts the channel from a
monomeric structure into a stable dimer of dimers complex.14–16 The channels calcium
sensitivity is regulated through the association of a kinase/phosphatase pair.14,17,24,90,93
Casein kinase 2 (CK2) and protein phosphatase 2A (PP2A) mediate the phosphorylation
and dephosphorylation of CaM’s threonine 80 (T80)14,17,24,90,92, with the phosphorylated
state being less calcium sensitive.14,90,92,93 The regulatory actions of CK2 and PP2A are
state-dependent; CK2 only phosphorylates T80 when the channel is closed, and PP2A
only dephosphorylates when the channel is open.14,92 Channel deactivation is the reverse
process with calcium dissociating from CaM, and the channel shifting back into a closed
state.13,90,95 SKCa channel activity largely follows that of free calcium near the channel,
thus the kinetics of the macroscopic current depend on the source and location of
calcium.14
KCa2.3 are expressed across a range of tissues, with high abundance in regions of
the brain, but also present at significant levels in peripheral tissues rich in smooth
muscle.96 KCa2.3 channels are present in mouse12,21,27, rat18, and human20,23,26,97
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Figure 3. Diagram of KCa2.3 channel with associated calmodulin and regulatory
proteins, CK2 and PP2A. KCa2.3 channels are six transmembrane channels composed
of four alpha subunits and activated by intracellular calcium binding to a constitutively
associated calmodulin. The channel’s calcium sensitivity is regulated through the
phosphorylation and dephosphorylation of a calmodulin threonine subunit by CK2 and
PP2A (ref).
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myometrium. KCa2.3 expression patterns in rat18 and human20 uterine tissue
demonstrated the greatest abundance in the smooth muscle layers of the myometrium,
and less abundant in the glandular epithelium and stroma of the endometrium. KCa2.3
channel transcript and protein expression levels are not consistent between mammals.
Mouse uterine tissue reveals a decrease in channel transcript22 and channel protein
expression22,27 during pregnancy beginning at mid-gestation. Rat uterine tissue showed
consistent KCa2.3 channel transcript and protein expression throughout gestation,
without the decrease seen in mouse tissue.18 KCa2.3 channel transcript and
expression20,23,87,97 are both decreased in late pregnant human uterine tissue compared to
non-pregnant tissue.
Further studies with KCa2.3 overexpression assessed the channels contribution to
murine uterine contractility. Brown et al.21 and Pierce et al.22 confirmed KCa2.3
expression was substantially increased in SK3T/T mice. Immunofluorescence revealed
distinct KCa2.3-positive staining in longitudinal bundles of mouse myometrium, with
SK3T/T mice having greater channel signal compared to SK3DOX mice in the myometrial
samples.21 SK3T/T uterine tissue strips had reduced force generation in myographical
studies when compared to wild type (WT) and SK3DOX mice, indicating that KCa2.3
overexpression diminishes uterine contractility.21,22 Induction of premature labor led to
delivery within 24 hours for WT and SK3DOX mice with SK3T/T mice failing to complete
delivery.21 These findings support the concept that KCa2.3 assists in negative feedback of
uterine contractility and is crucial to effective parturition.
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Modulation of SKCa channels
Fine tuning of SKCa relaxant effects is possible though pharmacological gating
modulation of the channel. Gating modulation of SKCa channels can occur through three
mechanisms: interaction with the pore (e.g., pore blockers such as apamin), modification
of the cytosolic calcium sensitivity of the channel (e.g., positive and negative
modulators), and amphiphilic structures acting by integration into the membrane.11
Apamin is a toxin isolated from honeybee venom that is a highly selective SKCa
channel blocker. Apamin is not a classic pore blocker, in that it does not physically
occlude the pore, rather it works through allosteric mechanisms to collapse the outer pore
of the channel.14,24,93 Apamin’s ability to block SKCa channels is different between
channel subtypes, with KCa2.2 displaying the highest sensitivity, KCa2.3 a moderate
sensitivity, and KCa2.1 the least.
Two main classes of chemotypes make up positive allosteric modulators (PAMs) of
SKCa channels. The bicyclic heterocyclic riluzole family activates all SKCa and IKCa
channels, with some also activating ion channels of other classes.93 The cyclohexyl-[2(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-yl]amine (CyPPA) family is highly
selective as they activate KCa2.2 and KCa2.3 channels and are completely inactive on
KCa2.1 and KCa3.1.25,93 While these families are structurally distinct, a PAM binding
pocket was identified between calmodulin and CaMBD on the SKCa interface, with the
ability to accommodate structurally diverse small molecules.15,24,25,93 Binding of a smallmolecule to the PAM binding pocket causes reorganization of side chains on the SKCa
channel and calmodulin.15,24 Side channel rearrangement is theorized to change
calmodulins interaction with channel regulatory proteins and alters channel state. This

21

action shifts the calcium activation curve toward lower concentration of calcium in a
concentration-dependent manner.13,16,17,24,25,90,92,93,98
Early myometrial studies with CyPPA employed myographical measurements of
contraction force and frequency of murine isolated myometrial strips. Myometrial
samples were taken from mice in varying states of gestation, specifically non-pregnant
(NP), day 10 (D10) and day 16 (D16) of pregnancy. These studies found increasing
concentrations of CyPPA had an ambiguous impact on uterine contraction frequencies
but significantly decreased contraction amplitudes. Contractions suppressed by CyPPA
could be restored with the addition of apamin.27 A preterm labor model was employed to
assess the effect of CyPPA in these conditions, and included contraction induction via
RU486 in pregnant mice. After phasic contractions developed a peritoneal injection of
CyPPA was administered to treatment group dams. Mice treated with CyPPA had a 3.4hour delay of preterm birth with increased pup retention when compared to the control
group.27 A small study utilizing non-pregnant and pregnant human myometrial samples
found CyPPA caused a concentration-dependent reduction of uterine contractility in both
gestational groups with concentrations of 60 μM abolishing contractions in both groups.26

Internal calcium store channels
The major source of calcium for contractions arises from L-type calcium
channels, but intracellular calcium release channels play a part by amplifying free
cytosolic calcium concentration through calcium-induced calcium release (CICR) from
internal stores. Movement of cytosolic calcium into the SR after activation of the SERCA
pump leads to internal store replenishment. IP3Rs are the predominate intracellular
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calcium release channel in the myometrium and control release of SR calcium after
activation.75,99–102 IP3R channels (IP3R1, IP3R2, IP3R3) are assembled from four large
subunits, each with a single IP3 binding site.31,100–103 IP3Rs are CICR receptors
commonly found in clusters in the SR membrane. Binding of an IP3 molecule to each
subunit of the channel exposes a calcium binding site. Free calcium from the cytoplasm
binds to each open calcium binding site allowing opening of the channel and calcium
release from stores (Figure 4).
Activation of an IP3R begins when intracellular IP3 binds to a pocket located
between the a and b domains of the IP3-binding core (IBC).100 Priming of the channel is
complete after all four subunits have bound IP3 (Figure 4), exposing the calcium binding
sites.90,91,94 Once calcium binds, a conformational change is triggered and the channel
opens.91,94 Strong and persistent extracellular signals can activate multiple IP3Rs to create
calcium waves.66,91,93 Calcium waves are further propagated as higher concentrations of
IP3 prime more IP3Rs to respond to calcium in their local environment and increase
channel opening probability. IP3Rs ability to activate neighboring IP3Rs, through
calcium release, demonstrates the importance of subcellular location in shaping
intracellular calcium signaling.100,102,103 IP3R calcium gating is biphasic, with low
calcium concentrations acting in a stimulatory manner, and higher concentrations
inhibiting channel opening.100 A decrease in IP3 generation triggers the IP3Rs to close,
diminishing intracellular calcium concentrations and allowing internal calcium stores to
refill.100
IP3 generation relies on ligand-operated Gq-protein coupled receptors (GqPCR)
activating phospholipase C-b (PLCb) to cleave the membrane phospholipid
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Figure 4. Calcium-induced calcium release from IP3R channels. IP3Rs are the
predominate intracellular calcium release channel in the myometrium and amplify
cytosolic Ca2+ levels through CICR from internal stores. IP3R channels are assembled
from four large subunits, each with a single IP3 binding site. When an IP3 molecule
binds to each subunit, Ca2+ binding sites are exposed. Ca2+ binding triggers a
conformational change, and the channel opens, releasing Ca2+ from internal stores into
the cytosol. IP3R, inositol 1,4,5-triphosphate receptors; CICR, calcium induced calcium
release.
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phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and IP3 (Figure
5).66,67,104,105 DAG activates protein kinase type C (PKC) which effects MLCP activity
through phosphorylation106 and IP3 controls mobilization of calcium from SR stores.

Agents that increase IP3 generation
Oxytocin
Oxytocin is a peptide hormone that is synthesized in the hypothalamus and stored
in the axon terminals of the posterior pituitary. During gestation the uterus, placenta, and
decidua also synthesize oxytocin. Oxytocin is released discontinuously from the posterior
pituitary and circulates as a free peptide in the bloodstream. Oxytocin is typically
controlled by neural mechanisms but hormones, such as estrogen, can stimulate oxytocin
release as well. Oxytocin receptors (OTR) are present in human myometrium,
endometrium, and decidua with expression of OTR increasing during late pregnancy and
early labor, allowing increased sensitivity of myometrial tissues to slight elevations of
oxytocin.66,107,108 The expression of myometrial OTR is high and uniform in the fundus
and corpus, and sharply declines in the lower uterine segment, isthmus, and cervix.109
The OTR is part of the Class I G-protein coupled receptor family and responds to
oxytocin binding in the myometrium by increasing cytosolic calcium levels through
multiple mechanisms. These include calcium entry via L-type calcium channels110,111,
increased IP3 generation through stimulation of the PLC pathway112–116 (Figure 5), and
limiting calcium extrusion by inhibiting Na+-Ca2+ exchange and Ca2+-ATPase.117,118 OT
activates RhoA which regulates acto-myosin coupling and calcium sensitivity of smooth
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Figure 5. GPCR mechanism of IP3 generation. Ligand-bound GPCR activates PLCb
which cleaves PIP2 into DAG and IP3.
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muscle contractile proteins.106 Activated RhoA further activates Rho kinase which
phosphorylates the myosin-binding subunit of MLCP leading to inhibition of myosinlight
chain dephosphorylation.119–121 OT activation also stimulates uterine contractility by
increasing release of PGF2a and arachidonic acid.114,115 Continuous oxytocin stimulation
can lead to loss of oxytocin receptors, demonstrated decreased number of oxytocin
binding sites and the very low receptor mRNA concentrations, culminating in receptor
desensitization.122–124
Prostaglandins
Prostaglandins (PGs) are lipids derived from arachidonic acid and synthesized
within human fetal amnion and chorion membranes and maternal decidua. PGs exert their
effect via G-protein coupled prostanoid receptors, of which many exist. PG receptors
include those for PGF2a (FP), PGE2 (EP1-4), thromboxane (TxA2), prostacyclin (IP), and
PGD (DP). Each PG receptor initiates a different intracellular signaling pathway, with
some PGs promoting a contractile response (FP, EP1, and EP3) and others a relaxing
effect (EP2, EP4, IP, and DP).104 The two major stimulating PGs present in human
myometrium are PGF2a and PGE, with levels of these PGs increasing as gestation
advances.104 PGF2a increases intracellular calcium levels by stimulating IP3-mediated
SR calcium release114–116 and increasing calcium influx through activation of NSCCs.
PGs also stimulate myometrial gap junction formation, allowing for sharing of
intracellular resources into neighboring MSMCs.125
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KCa channels and internal calcium store channels
Studies over the past decade have shown activation calcium for KCa channels
comes from a preferential source and can arise from plasma membrane calcium channels
or internal store release channels. Close proximity or local coupling has been found to
enhance plasma membrane channel activation by SR calcium release through local
IP3Rs. In rat and mouse cerebral artery smooth muscle cells, IP3-mediated calcium
release activates BKCa by elevating BKCa channel calcium sensitivity through local
molecular coupling.126 Erythrocyte lysate releases calcium from IP3-sensitive
intracellular stores and activates BKCa channels in rat basilar arterial myocytes via
increased cytoplasmic calcium levels.127 Ryanodine receptor channels also release
calcium from internal stores in smooth muscle SR and control the diameter of small
myogenic arteries through activation of BKCa channels.128
Calcium influx via vanilloid transient receptor potential subtype-4 (TRPV4)
channels selectively activate KCa3.1 and KCa2.3 channels in mouse mesenteric
arteries33,35, pulmonary microvascular endothelial cells (PMVECs), and pulmonary
arterial endothelial cells (PAECs).32 Tonic activity of endothelial KCa2.3 channels
creates a sustained hyperpolarization of the endothelial membrane potential, which is
then communicated to adjacent smooth muscle.129 This forms a positive feedback loop
that regulates membrane potential through increased intracellular calcium, either through
calcium entry or release from internal stores, activation of KCa channels and
endothelium-derived hyperpolarization.32,35
Coupling of TRPC3 channels to IP3R in arterial myocytes leads to T-type calcium
channel activation and vasoconstriction. Close spatial proximity between IP3R1 and
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TRPC3 establishes this isoform-selective functional interaction.130,131 Additionally IP3
was found to constrict cerebral arteries via an IP3R-mediated TRPC3 activation that was
independent of SR calcium release.132 Further investigation into this relationship found
TRP3 binds calcium-CaM at a site that overlaps with the IP3R binding domain.133 IP3Rmediated calcium release also activates TRPC1 channels in aortic myocytes134 and portal
vein smooth muscle cells.135 In cerebral artery smooth muscle cells calcium release for
SR stores is required for TRPM4 activity.136
A variety of neuronal cells have revealed a slow spontaneous current through
SKCa channels that are activated by RyR mediated calcium release from internal stores.14
Electron microscopy of Purkinje cell dendrites found colocalization of RyR and SK2
channels. Coupling of RyR and SK2 channels with VGCC channels is theorized to
underlie generation of afterhyperpolarization in these cells. Calcium influx through CaV
channels is required to induce CICR of internal stores through RyR, which then activates
SKCa channels.14 Spine SK channels are activated by calcium influx through R- and Ltype calcium channels as well as calcium released from internal stores through IP3R.14
The basis of this functional relationship includes calcium influx through a plasma
membrane calcium channel, that increases cytosolic calcium and opens internal store
calcium channels, either IP3 or RyR. Calcium release from internal stores is directed at
KCa channels due to their proximity, in these ER/SR projections. These studies
demonstrate the potential for local coupling of SKCa channels with internal store
channels and plasma calcium channels for regulation of calcium events. These studies
support the concept of internal stores and membrane KCa channel coupling as a primary
mechanism of calcium feedback control.
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Myometrial specific evidence for this concept came from unpublished rodent
studies by our laboratory, assessing CyPPAs ability to reduce oxytocin stimulated
contractility (Figure 6). Non-pregnant murine myometrial strips were pretreated with
CyPPA, to increase calcium sensitivity of KCa2.3, with increasing amounts of oxytocin
then applied. In the vehicle treated group, every addition of oxytocin increased uterine
contractility, but in the CyPPA pretreated group, oxytocin failed to increase mouse
myometrial contractility. These data support a role for internal calcium stores on KCa2.3
activation and myometrial negative feedback.
Preterm labor
One in ten babies is born prematurely in the United States and despite advancing
knowledge of risk factors and introduction of medical interventions, this incidence
remains consistent.137 Preterm birth (PTB) is defined as delivery prior to 37 weeks
gestation and is the leading cause of neonatal death and the second cause of childhood
death before the age of five. Infants who are born preterm are at a higher risk for lifelong
pulmonary, cardiac and neurodevelopmental disorders, as well as short-term
complications due to immaturity of organ systems.3 The United States has the greatest
incidence of PTB amongst high resource countries138 and is the only high-income country
in the top ten countries for number of preterm births in 2014139.
Spontaneous PTB accounts for approximately 70% of preterm deliveries, with the
remaining 30% accounting for medically induced birth due to maternal or fetal
complications.4 Spontaneous PTB may be idiopathic, or triggered by preterm premature
rupture of membranes (PPROM), or inflammation of the gestational tissues
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Figure 6. CyPPA suppression of spontaneous and oxytocin-induced contractions of
isolated mouse uterine strips. Isometric myography recordings of mouse uterine tissue
treated with either 10 μM CyPPA (A) or DMSO vehicle (B). Following treatment with
CyPPA, oxytocin failed to amplify uterine contractions and further dampened
contractions at 1 μM. CyPPA-suppressed contractions are restored by addition of the
KCa2.3 inhibitor apamin (0.6 μM).
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(myometrium, decidua, cervix, fetal membranes).4 Additional medical risk factors for
PTB include hypertension, placental abruption, placenta previa140, preeclampsia141,
eclampsia, previous preterm birth, previous delivery of a low birth weight infant, and low
pregnancy weight gain.142,143 Non-medical risk factors of preterm birth include
ethnicity144, maternal circadian dysregulation145–147, and air pollution148,149.
Identifying women who present with preterm contractions and will eventually
deliver preterm is a challenge for providers. The diagnosis of preterm labor generally is
based on presentation of regular uterine contractions accompanied by a change in cervical
dilation, effacement, or both, or initial presentation with regular contractions and cervical
dilation of at least 2 cm.150

Management of preterm labor
Therapies associated with improved neonatal outcomes include antenatal
corticosteroids for maturation of fetal lungs and the targeted use of magnesium sulfate for
fetal neuroprotection.150 The American College of Obstetrics and Gynecologists (ACOG)
recommends a single course of corticosteroids for pregnant women between 24 weeks
and 34 weeks of gestation who are at risk of delivery within 7 days.150 Preferred
corticosteroids include intramuscular administration of either two 12-mg doses of
betamethasone given 24 hours apart or four 6-mg doses of dexamethasone given every 12
hours.150 Magnesium sulfate has shown to reduce the risk and severity of cerebral palsy
in surviving infants if administered when birth is expected before 32 weeks gestation.151
ACOG supports short-term use of tocolytic medications in women with preterm
labor to suppress delivery long enough for the administration of antenatal steroids and
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magnesium sulfate, as well as transportation to a tertiary facility if necessary.150 Tocolytic
medications work by decreasing uterine tissue excitability and contractility to cause
uterine relaxation.
Tocolytic agents.
The importance of certain ion channels and receptor stimulated pathways to uterine
contractility is not a new concept. Tocolytic medications either inhibit ion channels or
block a stimulus to a second messenger pathway which can lead to off-target effects and
potential maternal and fetal adverse reactions. Tocolytic medications have not been
shown to reduce the rate of preterm delivery or improve neonatal outcomes.3,6,152
Tocolytic agents are given to suppress preterm labor long enough, for administration of
antenatal steroids, to accelerate fetal lung development.3,6,152 Only 80% of preterm labor
can be suppressed with tocolytics and at most for five days, which is merely a stop gap
and not a solution to the problem.3,5,152,153 The physiologic mechanisms underlying
tocolytic medications vary from systemic to targeted approaches, but their effectiveness
is limited and a new tocolytic medication has not been introduced in 35 years.154
Beta mimetics, such as terbutaline and historically ritodrine, are beta-adrenergic
receptor (b2AR) agonists that stimulate adenyl cyclase in myometrial cells through
GsPCR activation. GsPCR increases cAMP production, decreases intracellular calcium
and activates PKA.104,125 PKA inhibits PLCb and VGCCs155,156, decreasing intracellular
calcium levels. PKA also phosphorylates MLCK, altering MLCKs affinity for calciumcalmodulin, reducing phosphorylation of myosin light chains and promoting myometrial
relaxation.37,125,156–158
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Oxytocin receptor antagonists, such as atosiban, competitively bind oxytocin
receptors in the plasma membrane of myometrial cells preventing oxytocin-induced
calcium influx and IP3 generation.125
Magnesium sulfate is a general smooth muscle relaxant. Magnesium sulfate acts as a
calcium competitor by blocking entry of calcium via L- and T-type VGCC, which
reduces action potential generation and intracellular calcium levels.68,125 Magnesium also
enhances smooth muscle relaxation by enhancing KCa channel calcium sensitivity and
decreasing SR calcium release via decrease of PLCb generation.68,104,159–161
Prostaglandin inhibitors, such as ketorolac and indomethacin, block cyclooxygenase
(COX) enzyme from converting arachidonic acid into prostaglandin H2, and eventually
PGF2a and PGE.162,163
Calcium channel blockers, such as nifedipine, reduce the influx of calcium into
myometrial cells by blocking VGCC.125,155,164 Calcium influx from the extracellular
environment is largely responsible for the increase in intracellular calcium that is required
to activate the actin-myosin contractile machinery. Inhibition of plasma membrane
calcium channels can also prevent action potential propogation.104,155
As current tocolytic methods are not effective and only suppress labor for a few days,
the possibility of a tocolytic that enhances an innate uterine relaxation feedback system
should be investigated. Rather than stopping a stimulus to contraction, fine tuning of a
feedback system could be employed to relax the uterus.

34

CHAPTER III
MATERIALS AND METHODS

General materials and methods

Patient selection
Approval for the collection of uterine biopsies was obtained from the University
of South Alabama’s Institutional Review Board. Fully informed written consent was
sought from all patients participating in this study by either research personnel or medical
providers from the Department of Obstetrics and Gynecology. Tissue was obtained from
women undergoing a hysterectomy for a gynecological condition, or those having a
cesarean section for delivery of a child.

Human tissue samples
Full thickness uterine samples from non-pregnant women (mean age 41.4; range
27 - 69 years; n = 22) were collected in the operating room at the time of hysterectomy
and excised from the upper aspect of the lower uterine segment. In the operating theater,
samples were placed in HEPES buffer and immediately transported to the lab for
processing. All studies performed with non-pregnant samples were conducted within 24
hours of excision time. Indications for hysterectomy included: dysmenorrhea, uterine
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fibroids, endometriosis, uterine prolapse, and risk of cancer. Exclusion criteria for patient
participation included: patient under the age of 18 years or presence of an infection
outside the limitations of a BSL-2 laboratory. Table 1 describes the demographic and
clinical data of included non-pregnant patients.

Table 1. Demographic and clinical data of non-pregnant women.
Age, years
27 - 69 years (mean 41.4)
Ethnicity
Caucasian: 12
African American: 9
Latino/Hispanic: 1
Indications for hysterectomy
Dysmenorrhea: 19
(subject may have multiple reasons)
Uterine fibroids: 6
Endometriosis: 2
Risk of cancer: 2
Uterine prolapse: 2
Additional gynecological history
History of abnormal PAP smear: 9
(subject may have multiple conditions)
Ovarian cysts: 5
Full thickness uterine samples from pregnant women (gestational age range 28+6
- 39+3 weeks; mean maternal age 29.1; range 21 - 45 years; n = 19) were collected in the
operating room at the time of cesarean section and excised from the upper edge of the
lower uterine segment incision (except for one patient with extensive abdominal
adhesions that required the sample be taken from the lower edge), immediately after the
baby was born. Biopsies included term, non-laboring (n = 14), preterm, non-laboring (n =
3), and preterm, laboring (n = 2), from patients undergoing a repeat cesarean section (n =
17) or a first-time cesarean section (n = 2). In the operating theater, samples were placed
in HEPES buffer and stored in 4ºC refrigerator until collected by research personnel. All
studies performed with pregnant samples were conducted within 48 hours of excision
time. Indications for cesarean section included: breech presentation, previous cesarean
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section, maternal request, premature rupture of membranes, preeclampsia/eclampsia,
gestational hypertension, and previous myomectomy. Exclusion criteria for patient
participation included: patient under the age of 18 years or presence of an infection
outside the limitations of a BSL-2 laboratory. Table 2 describes the demographic and
clinical data of included pregnant patients.

Table 2: Demographic and clinical data of pregnant women.
Maternal age, years
21 - 45 years (mean 29.1)
Ethnicity
Caucasian: 10
African American: 8
Asian: 1
Gestational age at delivery, weeks
28+6 - 39+3 weeks (mean 37+1)
Laboring status
Term, non-laboring: 14
Preterm, non-laboring: 3
Preterm, laboring: 2
Indications for cesarean section
Previous cesarean: 16
(subject may have multiple indications)
Maternal request: 1
Breech presentation: 1
Preeclampsia/eclampsia: 2
Premature rupture of membranes: 2
Gestational hypertension: 1
Previous myomectomy: 1
Additional gynecological history
History of abnormal PAP smear: 6
(subject may have multiple conditions)
Uterine fibroids: 3
Endometriosis: 1
Materials
Common solutions used throughout these studies included HEPES and PBS
buffer. Phosphate-buffered saline (PBS), pH 7.4 containing (in mM): 135 NaCl, 1.3 KCl,
3.2 Na2HPO4, and 0.5 KH2PO4. HEPES buffer, pH 7.4 containing (in mM): 134 NaCl, 6
KCl, 1 MgCl2, 2 CaCl2, 10 HEPES acid, 10 glucose.

37

Figure 7. Dissection and allocation of human uterine tissue. (A) Tissue is excised
from the anterior aspect of the uterus. (B) Tissue is transported to the lab and washed in
HEPES buffer. (C) Portions of the myometrium without or without endometrium are
dissected out for freezing and immunofluorescent staining. (D) Myometrium is sectioned
further into strips and (E) sewn into rings with suture. (F) Uterine rings are mounted
around myograph pins, with one pin attached to a force transducer for measurements.
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Immunofluorescent microscopy
Samples of fresh human uterine tissue were rinsed with HEPES buffer, and
sections of tissue including a combination of myometrium or myometrium and
endometrium were dissected (Figure 7). Sections were placed in a Tissue-Tek cryomold
(Sakura Finetek) and covered with Tissue-Tek O.C.T. compound (Sakura Finetek).
Tissue was then flash frozen in the cryomolds by liquid nitrogen. Samples were moved to
the -80ºC freezer for storage. Frozen samples were sliced via cryostat into 10 micron or
20 micron thick sections and placed on slides by lab personnel of the University of South
Alabama Pathology Department. Tissue slices were fixed with 5% paraformaldehyde and
permeabilized with 0.2% Triton X-100 (Sigma) in PBS. Tissues were blocked with 2%
BSA and 10% normal goat serum in 0.2% Triton X-100 (Sigma) in PBS, then incubated
with KCa2.3 primary antibody (rabbit, anti-KCNN3; Alomone Labs; 1:250) overnight at
4ºC. The following day tissue was stained with secondary antibody (goat anti-rabbit,
Alexa Fluor 568; Molecular Probes, Invitrogen; 1:500). For dual staining images the
tissue were then incubated with IP3R primary antibody (monoclonal, mouse, recombinant
anti-IP3R; Abcam; 1:250) overnight at 4ºC. The next day tissue was stained with
secondary antibody (goat anti-mouse, Alexa Fluor 488; Molecular Probes, Invitrogen;
1:500). Tissues were stained for nuclear visualization (NucBlue; ThermoFisher) for ten
minutes and then mounting media and coverslips were applied. The specificity of
secondary antibodies were tested by staining myometrial samples with only the red
(Alexa Fluor 568) or green (Alexa Fluor 488) secondary antibodies. Samples were
viewed with a Nikon A1 confocal and secondary only controls demonstrated no
fluorescent signal. Negative control images for red and green secondary antibodies can be
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found in Figure 40 in Appendix A. Tissues were imaged with a Nikon A1 confocal
microscopy with imaging conducted under identical conditions for all preparations.

Tissue myography

Uterine ring preparations
Fresh human uterine tissue was washed in HEPES buffer and small strips
measuring 8-10 mm in length, 3 mm in width and 3 mm in depth were created from
myometrial tissue. These strips were sutured with 6-0 Prolene polypropylene suture
(Ethicon) in an end-to-end fashion to create myometrial rings. Myometrial rings were
mounted around the myographical pins, with one pin connected to a force transducer and
the other to an adjustable micrometer (Figure 7). These pins were suspended in an organ
bath containing 5 mL of prewarmed (37ºC) and gassed (95% O2, 5% CO2). All
experiments were conducted under these conditions.
Myographical recordings
Two myography machines were used: a Danish Myo Technology (DMT) multi
myograph system model 610M and a DMT multi myograph system model 620M. Once
myometrial rings were mounted, they were incrementally stretched until they held 1-4
mN of tone. The rings were allowed to rest until they developed spontaneous
contractions. Following equilibration, uterine rings exhibited a regular pattern of
spontaneous contractions and therefore it was not necessary to induce contractions with a
chemical stimulant. Contraction-response experiments were initiated after four
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spontaneous and consistent contractions occurred. Uterine rings that did not develop
spontaneous contractions were excluded from experiments.
Drugs
Concentration-response curves for oxytocin, prostaglandin F2a, m-3M3FBS, and
U73122 were conducted on non-pregnant and pregnant tissue to confirm dosages used in
other studies and determine concentrations for drugs not previously used on myometrial
tissue. Concentration-response analysis is located in Figure 41 in Appendix A. Other
drugs including CyPPA, apamin, cyclopiazonic acid, and nifedipine were used in
concentrations referenced from previous internal and external studies.
CyPPA, prostaglandin F2a, m-3M3FBS, and U73122 (each dissolved in DMSO)
were purchased from Tocris. Oxytocin and cyclopiazonic acid (each dissolved in DMSO)
were purchased from Abcam. Apamin (dissolved in DMSO) was purchased from R&D
systems. Nifedipine (dissolved in DMSO) was purchased from Sigma. Exogenous
activators and inhibitors were added separately to the tissue bath in 20-minute intervals.
Statistical analysis
Analogue signal output was digitalized with a PowerLab and visualized and
analyzed using LabChart software (both AD Instruments). Independent contractions are
described as any deflection of >10% of maximum contraction amplitude (for the
individual recording) and then drops below 20% of maximum peak. If a waveform has
two peaks and drops to below 20% of the max amplitude, it will be counted as two
contractions. Parameters assessed included frequency (contractions/minute), amplitude
(gram tension; mN), and area under the curve (AUC), which is calculated by taking the
integral of the selected tracing over the duration of time for the selected tracing (mN x
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min). Statistical analyses were performed using non-parametric tests as appropriate for
the desired comparisons using GraphPad prism 9 software (GraphPad software).
Individual tests are listed in the results section. Data were normalized to spontaneous
contraction data or agonist-augmented data as appropriate. Data are reported as median
(interquartile range, IQR) with P < 0.05 considered statistically significant.
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CHAPTER IV
RESULTS

Evaluate the expression and distribution of KCa2.3 and IP3R channels in human
myometrium
To qualitatively assess the location of KCa2.3 and IP3R channels within
myometrial smooth muscle, thin sections of myometrium were probed for channel
expression via immunofluorescence. KCa2.3 channel, stained in red, and IP3R channel,
stained in green, were evaluated for myometrial expression and distribution, as well
changes due to pregnancy. Muscle fibers in the myometrium are oriented along different
planes, therefore signal took on an elongated appearance when muscle fibers were cut
obliquely and a rounded form when cut horizontally. Orientation of muscle fibers and
tracts of signal were more apparent in non-pregnant tissue and corresponded to sweeping
motions of channel expression viewed amongst truncated circular shapes (Figure 8). In
pregnant tissue these distinct fibers were replaced with more segmental orientation and
indistinct alignment of muscle fibers (Figure 10).
In non-pregnant myometrium KCa2.3 signal was generally diffuse with smaller
punctated regions of signal. IP3R signal found similar characteristic to KCa2.3
expression but with larger densities of signal noted within the tissue (Figure 8). KCa2.3
signal was more variable than IP3R signal in non-pregnant tissue as some samples
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demonstrated very distinct and clear expression (Figure 9A) and others were a more
diffuse pattern of distribution (Figure 9B). IP3R channel expression and distribution
generally remained the same across the assorted channel patterns. There was not a
consistent ore representative staining pattern of KCa2.3 and IP3R within non-pregnant
tissue as can be seen by non-pregnant sample images (Figure 9A and 9B). There were
disparities noted in co-localization of channel signal as Figure 9A shows an expression
pattern in which KCa2.3 and IP3R channels are distinctive with no co-expression and
Figure 9B has a greater degree of co-expression. Immunofluorescent staining of multiple
histological samples discovered an assortment of distribution and expression patterns
within non-pregnant tissues. Glandular and stromal tissue were identified in non-pregnant
myometrium and these tissues had different configurations than smooth muscle fibers
with either KCa2.3 and nuclei or just IP3R but rarely co-localization (Figure 9B). The
nuclear arrangement seen in non-pregnant tissue was dense and tight, with many smaller
nuclei visualized in each image.
In pregnant myometrial samples cellular density decreased as uterine myocytes
become hypertrophied, resulting in a nuclear staining pattern that is less condensed
(Figure 10). IP3R channel distribution patterns remained generally consistent between
non-pregnant and pregnant tissue samples, with slight variation in background dispersion
(Figure 10). The greatest change observed between tissues of different gestational states
was the expression and distribution patterns of KCa2.3 channels. KCa2.3 channels in
pregnant tissue tended to be more diffusely distributed with varying intensities of
expression (Figure 10). Generally, there was a greater loss of punctated and clustered
regions of signal in pregnant tissue when compared to non-pregnant tissue.
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Figure 8. KCa2.3 and IP3R channels are present in non-pregnant human
myometrium. Individual channel signal was visualized with KCa2.3 channels stained
red, IP3 channels stained green, and nuclei blue. A merged image of channel signals is
presented in the far-right box. Areas of distinct signal were present as well as areas of
potential co-expression seen in yellow.
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Figure 9. Varying staining patterns of KCa2.3 and IP3R channels are visualized in
non-pregnant tissue. Non-pregnant myometrium revealed an assortment of staining
patterns for KCa2.3 and IP3R channels with some having distinct and punctated signal
(A) and others with a more diffuse appearance of signal (B). Amount of co-expression
also varied amongst samples.

Figure 10. KCa2.3 and IP3R channels are present in pregnant human myometrium.
KCa2.3 channels are stained red, IP3 channels are stained green, and nuclei blue. A
merged image of channel signals is presented in the far-right box. Areas of distinct signal
were present as well as areas of potential co-expression seen in yellow.
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Figure 11. Expression and distribution patterns of KCa2.3 and IP3R are variable in
pregnant tissue. A range of staining patterns for KCa2.3 and IP3R channels were
observed in pregnant tissue with a greater number of pregnant samples having a more
diffuse KCa2.3 signal (A) than non-pregnant tissue. Patterns of co-localization of KCa2.3
and IP3R channels also varied within pregnant tissue (B).

Characterize spontaneous and augmented contractions of human uterine tissue

Reproductive state and spontaneous contraction characteristics
To characterize spontaneous contractions of non-pregnant and pregnant tissue,
uterine rings were mounted around myograph pins and submersed in warmed (37ºC)
HEPES buffer. The rings were stretched until they held 1-4 mN of tone and allowed to
rest until spontaneous contractions developed. Multiple uterine rings were sampled from
the same patient to characterize aspects of individual subjects as well as the reproductive
status as a group. Non-pregnant samples (n = 109) from 18 subjects and pregnant samples
(n = 159) from 19 subjects were assessed for innate frequency and amplitude of
contractions. Tissue samples generally developed spontaneous contractions in 1-3 hours
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but 6 of 156 (3.85%) non-pregnant samples and 41 of 216 (18.98%) pregnant samples did
not develop spontaneous contractions after 3.5 hours.
Comparison of non-pregnant and pregnant spontaneous contractions began with
plotting the frequencies (Figure 12) and amplitudes (Figure 13) of non-pregnant (n = 109)
and pregnant (n = 159) samples. These graphs revealed observable differences in
distributions and therefore histograms for frequency and amplitude were constructed.

Figure 12. Frequencies of human uterine contractions in non-pregnant and
pregnant tissue. Individual samples are plotted to display the differences in clustering
pattern between non-pregnant (A, n = 109) and pregnant (B, n = 159) tissue. Horizontal
lines represent median and IQR.
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Analysis demonstrated that pregnant tissue had a narrower window of
spontaneous frequency as 75.5% of pregnant samples (n = 159) had a frequency less than
0.4, compared to 46.8% of non-pregnant samples (n = 109) having a frequency less than
0.4 (Figure 14). Amplitude histograms of non-pregnant and pregnant tissue reveal right
skewed distributions but to a greater extent in pregnant tissue (Figure 15).

Figure 13. Amplitudes of human uterine contractions in non-pregnant and pregnant
tissue. Individual samples are plotted to display the differences in clustering pattern
between non-pregnant (A, n = 109) and pregnant (B, n = 159) tissue. Horizontal lines
represent median and IQR.
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Contraction frequency was significantly different between non-pregnant and
pregnant tissue (0.53 [0.86-0.31] vs 0.26 [0.35-0.20], P < 0.0001) which supports the
theory that reproductive status alters innate contraction characteristics (Figure 16A).
Amplitude of contractions was also different (Figure 16B), with pregnant tissue
amplitude significantly reduced compared to non-pregnant samples (10 [16-6.2] vs 2.4
[6-0.96], P < 0.0001). This finding supports the idea that pregnancy affects contractility,
but the initial theory was that amplitude of pregnant contractions would be greater than
non-pregnant contractions.
This trend of variation, noted in reproductive status comparison, was also
observed between different samples from the same subject. Myographical recordings of
spontaneous contractions showed noticeable variations of frequency, amplitude, and
waveform morphology (Figure 17).
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Figure 14. Histogram of spontaneous human uterine contraction frequencies.
Frequency distribution of uterine contraction frequencies of non-pregnant (A) and
pregnant (B) samples are skewed to the right. Frequencies of pregnant tissue is right
skewed to a greater extent.

Figure 15. Histogram of spontaneous human uterine contraction amplitudes.
Frequency distribution of uterine contraction amplitudes of non-pregnant (A) and
pregnant (B) samples are skewed to the right. Amplitudes of pregnant tissue are skewed
more to the right compared to non-pregnant contractions.
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Figure 16. Comparison of frequencies and amplitude between non-pregnant and
pregnant samples. Contraction frequency was significantly reduced in pregnant (n =
159) vs non-pregnant (n = 109) tissue samples. Contraction amplitude of pregnant tissue
was also significantly less than non-pregnant tissue. Box plot of medians with min and
max values represented by whisker bars. Data were analyzed by Mann-Whitney test.
**** P < 0.0001.
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Figure 17. Variation of contraction frequency and amplitude within same subject
samples. Myographical recordings demonstrate different contraction frequencies,
amplitudes, and waveform morphologies amongst tissue samples from the same pregnant
subject.
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Functional impact of CyPPA on human uterine smooth muscle contractions
To investigate the effects of KCa2.3 positive modulation via CyPPA on human
uterine contractions, non-pregnant and pregnant uterine rings were mounted around
myograph pins in an organ bath and allowed to develop spontaneous contractions via
methods previously described. Increasing amounts of CyPPA (3 µM, 10 µM, 30 µM)
were added to the organ bath in 20-minute increments. Myographical recordings
demonstrate the changes in contraction frequency and amplitude with increasing CyPPA
concentrations (Figure 18).
Individual sample response to increasing concentrations of CyPPA was
inconsistent regarding frequency and amplitude changes. Figures 19 and 20 reveal these
irregularities, as progression of frequency and amplitude over the course of CyPPA
treatment in non-pregnant and pregnant tissue are compared side by side. Collected data
revealed 30 µM CyPPA significantly reduced the frequency of spontaneous contractions
in both the non-pregnant (0.28 [0.45-0.09] vs 0.83 [1.17-0.37], P = 0.0001; Figure 21A)
and pregnant samples (0.14 [0.19-0] vs 0.27 [0.46-0.2], P < 0.0001; Figure 21B). There
was also significant reduction of frequency between 3 µM and 30 µM CyPPA
concentrations in the pregnant group (0.24 [0.41-0.17] vs 0.14 [0.19-0], P = 0.002; Figure
21B). Analysis of amplitude changes revealed a statistically significant decrease in
uterine contraction amplitude in non-pregnant samples between 3 µM CyPPA and 30 µM
CyPPA concentrations (13.9 [21.12-9.3] vs 8.51 [18.14-2.75], P = 0.006; Figure 22A).
Pregnant sample amplitudes were also significantly reduced between spontaneous
contractions and 30 µM CyPPA (2.97 [7.91-1.37] vs 0.5 [2.16-0], P < 0.0001) and
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between 3 µM CyPPA and 30 µMCyPPA concentrations (2.54 [10.86-1.18] vs 0.5 [2.160], P < 0.0001; Figure 22B).

Figure 18. Effect of CyPPA on human uterine contractions in concentrationresponse studies. Myographical recordings demonstrating the effect of increasing
CyPPA concentrations (3 µM, 10 µM, 30 µM) on spontaneously contracting uterine rings
from non-pregnant (NP) and pregnant (P) human uterine tissue.
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Figure 19. Effect of increasing CyPPA on human uterine contraction frequency of
individual samples. Summary of contraction frequency changes of individual uterine
rings with increasing CyPPA concentration from non-pregnant (A, n = 8) and pregnant
(B, n = 14) human uterine tissue.

Figure 20. Effect of increasing CyPPA on human uterine contraction amplitude of
individual samples. Summary of contraction amplitude changes of individual uterine
rings with increasing CyPPA concentration from non-pregnant (A, n = 8) and pregnant
(B, n = 14) human uterine tissue.
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Figure 21. Summary of increasing CyPPA concentration on contraction frequency.
Increasing concentrations of CyPPA reduced contraction frequencies in non-pregnant (A;
n = 8) and pregnant (B; n = 14) tissue samples. Significant reductions in contraction
frequency were found in non-pregnant and pregnant tissue samples. Box plot of medians
with min and max values represented by whisker bars. Data were analyzed by Friedmann
test with Dunn post hoc test for multiple comparisons. ** P ≤ 0.01, *** P ≤ 0.001, ****
P < 0.0001.
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Figure 22. Summary of increasing CyPPA concentration on contraction amplitude.
The concentration-response displays a significant reduction of contraction amplitude with
cumulative additions of CyPPA in non-pregnant (A; n = 8) and pregnant (B; n = 14)
tissue samples. Box plot of medians with min and max values represented by whisker
bars. Data were analyzed by Friedmann test with Dunn test for multiple comparisons. **
P ≤ 0.01, **** P < 0.0001.
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Contraction frequency and amplitude are components of the overall force
generated by a contraction. Waveforms can vary in morphology leading to frequency and
amplitude values lacking representation of contractility. To better assess overall changes
to uterine contractions, shifts in AUC after increasing CyPPA concentrations were
evaluated. Comparing changes in AUC, to frequency and amplitude, can infer the weight
of these individual components to overall contractility. Graphical representation of
changes in AUC with increasing CyPPA in non-pregnant and pregnant samples reveals
similarities between non-pregnant and pregnant tissue with outliers (Figure 23).

Figure 23. Effect of increasing CyPPA on human uterine contraction AUC of
individual samples. Summary of AUC changes of individual uterine rings with
increasing CyPPA concentration from non-pregnant (A; n = 8) and pregnant (B; n = 14)
human uterine tissue.
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There was significant decrease in contraction AUC in non-pregnant samples
between spontaneous contractions and 10 µM CyPPA (6296.5 [10546.75-5464] vs 4698
[7048.5-2902.75], P = 0.02) and spontaneous contractions and 30 µM CyPPA
concentrations (6296.5 [10546.75-5464] vs 2421 [4731.25-1287.5], P < 0.0001; Figure
24A). Pregnant tissue demonstrated a significant reduction in AUC between spontaneous
contractions and 30 µM CyPPA (2409.5 [6068-756.03] vs 746 [2662.25-266.75], P <
0.0001) and between 3 µM and 30 µM CyPPA concentrations (2002.5 [4611.75-612.7]
vs 746 [2662.25-266.75], P < 0.0001; Figure 24B).

Figure 24. Summary of increasing CyPPA concentration on contraction AUC. The
concentration-response displays a significant reduction of contraction AUC with
cumulative additions of CyPPA in non-pregnant (A; n = 8) and pregnant (B; n = 14)
tissue samples. Box plot of medians with min and max values represented by whisker
bars. Data were analyzed by Friedmann test with Dunn test for multiple comparisons. * P
< 0.05, **** P < 0.0001
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To compare the effect of CyPPA between non-pregnant and pregnant tissues, raw
data needed to be normalized to spontaneous contractions within each gestational group.
The normalized values of frequency, amplitude, and AUC after treatment with 30 µM
CyPPA were compared between non-pregnant and pregnant tissue. Contraction
frequencies (P = 0.6875; Figure 25A) and AUC (P = 0.3828; Figure 25C) were not
statistically different between gestational groups, demonstrating CyPPA has equal effects
on those contraction indices regardless of gestational status. CyPPA significantly reduced
contraction amplitude between non-pregnant and pregnant samples (77.99 [99.21-12.85]
vs 34.4 [51.43-0], P = 0.016; Figure 25B). These results indicate that CyPPA has greater
effects on diminishing contraction amplitude in human pregnant samples, but not to the
point that it significantly reduces overall contractility.

Assess the role of the internal calcium stores in KCa2.3 modulation of human
uterine contractility

Examine CyPPA attenuation of uterine contractions with oxytocin treatment
To investigate the relationship between internal store release and the relaxing
effects of KCa2.3 positive modulation, increasing OT concentrations (0.3 nM, 1 nM, 3
nM) were added every 20 minutes to pregnant tissue (n = 13) already incubated with 10
µM CyPPA. The hypothesis for this portion of the study is that increasing internal store
calcium release, via OT and GPCR mediated mechanisms, will provided directed calcium
to KCa2.3 channels for activation. As the calcium sensitivity of these channels is already
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Figure 25. Comparison of non-pregnant and pregnant human myometrial samples
after treatment with 30 µM of CyPPA. Treatment with 30 µM of CyPPA did not
significantly affect contraction frequency (A) or AUC (C) between non-pregnant (n = 8)
and pregnant samples (n = 14). Contraction amplitude (B) was significantly reduced in
pregnant samples, displaying greater effect of CyPPA on pregnant tissue. Box plot of
medians with minimum and maximum values represented by whisker bars. Data were
analyzed by Wilcoxon test. * P < 0.05
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increased though CyPPA positive modulation, amplification of internal store release
should further enhance uterine relaxation.
Inconsistent responsiveness to OT was noted in pregnant uterine tissue, as can be
demonstrated by plotting response to frequency, amplitude, and AUC of individual
samples (Figure 26). Initial incubation with CyPPA and then subsequent increasing
concentrations of OT did not yield significant changes to overall frequency (P = 0.23;
Figure 27A), amplitude (P = 0.6; Figure 27B), or AUC (P = 0.16; Figure 27C). While the
lack of significance does not support the internal stores hypothesis, the general trend of
OTs inability to overcome the relaxant effects of CyPPA was noted (Figure 27).
This same mechanism of proposed internal store amplification of KCa relaxant effects
was tested to assess if altering the addition order and concentration of OT and CyPPA
effected overall contractility. For this arm of the study, pregnant samples were incubated
with 1 nM OT for 20 minutes and then administered increasing dosages of CyPPA (3
µM, 10 µM, 30 µM) every 20 minutes. Variations in contractile response to the CyPPA
pretreatment protocol did not appear to be as numerous, but outliers, specifically when
analyzing changes in amplitude (Figure 28B), were identified when individual sample’s
contractile response were plotted (Figure 28).
Overall contractile effects of OT pretreatment can be seen in Figure 29. Analysis
demonstrated a significant decline in contraction frequency between 1 nM OT and 10 µM
CyPPA (0.313 [0.49-0.19] vs 0.15 [0.28-0.11], P = 0.04) as well as between 1 nM OT
and 30 µM CyPPA (0.313 [0.49-0.19] vs 0.067 [0.11-0.044], P = 0.0005; Figure 29A).
Amplitudes of contractions were greatly reduced by 30 µM CyPPA as significance was
demonstrated between it and all other aspects of the protocol:

63

Figure 26. Effect of CyPPA pretreatment protocol on pregnant human uterine
contraction frequency, amplitude, and AUC of individual samples. Changes to
frequency (A), amplitude (B), and (C) AUC of individual uterine samples from pregnant
patients (n = 13). Line plots demonstrate a variable response to CyPPA and OT in
pregnant tissue samples.
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Figure 27. Effects of CyPPA and OT treatment on human myometrial contractility.
Pregnant tissue samples (n = 13) were incubated with 10 µM CyPPA with increasing
concentrations of OT added to the myograph bath every 20 minutes after. Effects on
frequency (A), amplitude (B), and AUC (C) of contractions were examined. Box plot of
medians with min and max values represented by whisker bars. Data were analyzed by
Friedmann test with Dunn test for multiple comparisons.
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1 nM OT (1.71 [4.2-0.53] vs 0.83 [1.65-0.18], P = 0.02), 3 µM CyPPA (2.01
[4.65-0.58] vs 0.83 [1.65-0.18], P = 0.0001), and 10 µM CyPPA (1.81 [4.19-0.63] vs
0.83 [1.65-0.18], P = 0.003; Figure 29B). As would be expected from significant
reductions in contraction frequency and amplitude, AUC exhibited statistical significance
on a few levels. The AUC was lessened between 1 nM OT and 10 µM CyPPA (9883
[23962-353] vs 5803 [17750-2171], P = 0.04), 1 nM OT and 30 µM CyPPA (9883
[23962-353] vs 3798 [8498-1262.5], P = 0.0003), and 3 µM CyPPA and 30 µM CyPPA
(8678 [23293-2849.5] vs 3798 [8498-1262.5], P = 0.003; Figure 29C).
The previous studies compared results among the same treatment group, which
only found significance with OT pretreatment and increasing concentrations of CyPPA.
Choosing what end points to compare posed two questions: (1) is there a difference if the
same concentrations of agents are added but in different orders and (2) were the overall
end point of the two treatment protocols significantly different in their ability to relax
contractions. To compare the two groups, contraction traits (frequency, amplitude, and
AUC) were normalized to spontaneous contractions (control). Figure 30A examines
shifts in contractility (AUC) when the same concentration of agents, 10 µM CyPPA and 1
nM OT, are added in different orders. To assess the overall end points of each treatment
protocol, contractility (AUC) at the end of each protocol were compared to spontaneous
contractions. This meant that the concentration of agents at end point of the CyPPA
pretreatment protocol was 10 µM CyPPA and 3 nM OT, and the OT pretreatment
protocol was 1 nM OT and 30 µM CyPPA. These results can be found in Figure 30B.
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Figure 28. Effect of OT pretreatment protocol on pregnant human uterine
contraction frequency, amplitude, and AUC of individual samples. Changes to
frequency (A), amplitude (B), and (C) AUC of individual uterine samples from pregnant
subject (n = 13). Line plots reveal inconsistent responses to OT and CyPPA but with a
trend of reduction in AUC.
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Figure 29. Effects of OT and CyPPA treatment on human myometrial contractility.
Pregnant tissue samples (n = 13) were incubated with 1 nM OT with increasing
concentrations of CyPPA added to the myograph bath every 20 minutes after. Effects on
frequency (A), amplitude (B), and AUC (C) of contractions were examined. Box plot of
medians with min and max values represented by whisker bars. Data were analyzed by
Friedmann test with Dunn test for multiple comparisons. * P < 0.05, ** P ≤ 0.01, *** P ≤
0.001
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Figure 30. Difference in AUC of contractions between two treatment protocol
involving varying concentrations and application order of CyPPA and OT. (A)
Treatment protocols with concentrations of agents conserved but added to the organ bath
in a different order (B) Treatment protocol assessing the end point of maximal
concentrations of difference agents. Box plot of medians with min and max values
represented by whisker bars. Data were analyzed by Wilcoxon test. * P < 0.05

Alterations to CyPPA augmented contractions after internal store depletion
To determine the ability of CyPPA to diminish uterine contractions in the
presence of internal store depletion via SERCA blockade, non-pregnant and pregnant
uterine rings were mounted and allowed to develop spontaneous contractions. Nonpregnant (n = 9) and pregnant (n = 10) contracting samples were incubated with 20 µM
CPA (SERCA inhibitor) for 20 minutes or continue with control contractions, prior to the
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addition of increasing amounts of CyPPA (3 µM, 10 µM, 30 µM) every 20 minutes.
Figure 27 portrays a representative myograph recording of the protocol and standard
contractile effects on amplitude, frequency, and waveform morphology. A common
observation of this protocol was an increase in contraction frequency after the addition of
CPA which can be seen in Figure 31B.

Figure 31. Myographical recording of changes to contractions during execution of
CPA and CyPPA protocol. Application of CPA was found to cause waveform changes
in myometrial tissue samples. In this uterine sample a reduction of amplitude, an increase
in frequency, and the development of tone was noted in the lower panel of this recording.
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To compare the two treatment groups, contraction features were normalized to
either spontaneous contractions in the control arm or to CPA modified contractions in the
CPA and CyPPA arm. Normalizing the data controlled for the CPA induced contractile
changes, allowing for comparison of CyPPA effects between the groups. Normalized
values of frequency, amplitude and AUC are presented in Figure 32. Normalized
frequency results for non-pregnant samples were not significant between the control and
CPA treatment group, with calculated P values of 0.65 for 3 µM CyPPA, 0.91 for 10 µM
CyPPA, and > 0.99 for 30 µM CyPPA (Figure 32A). Non-pregnant contraction amplitude
comparison between control and CPA pretreated groups were not statistically different at
3 µM CyPPA (P > 0.99), 10 µM CyPPA (P > 0.99), or 30 µM CyPPA (P = 0.11) (Figure
32C). Overall contractility, in the form of normalized AUC for non-pregnant tissue, did
not support significance and included P = 0.57 for 3 µM CyPPA, P = 0.82 for 10 µM
CyPPA, and P = 0.38 for 30 µM CyPPA (Figure 32E).
Pregnant myometrial sample data showed no difference in contraction frequency
between control and treatment groups with P values of 0.23 for 3 µM CyPPA, 0.49 for 10
µM CyPPA, and 0.32 for 30 µM CyPPA (Figure 32B). Contraction amplitude
comparison between pregnant control and CPA pretreated groups did not demonstrate
significance at 3 µM CyPPA (P = 0.85), 10 µM CyPPA (P > 0.99), or 30 µM CyPPA (P
= 0.56) (Figure 32D). Overall contractility, in the form of normalized AUC in pregnant
samples, included P = 0.92 for 3 µM CyPPA, P = 0.56 for 10 µM CyPPA, and P = 0.23
for 30 µM CyPPA (Figure 32F).
Blocking SERCA in myometrial smooth muscle allowed us to remove the internal
calcium stores and test its role in uterine contractions. We found depleting SR stores did
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not hamper CyPPA’s ability to diminish uterine contractions, suggesting that in an
unstimulated state, internal stores are not a main contributor to SK3 channel activation.

Characterize effects of increased internal calcium release on spontaneous and
KCa2.3 modulated contractions by GPCR and PLC agents
To initially characterize the effects of internal calcium store release on
spontaneous contractions, GPCR and PLC pathways were augmented through different
agents. GPCR agonists included oxytocin and PGF2a, both of which activate IP3R
channels through increased formation of IP3 as one of their mechanisms. Stimulation of
the PLC pathway also increases IP3 generation and internal store release, and was
activated via m-3M3FBS, and inhibited with U73122. Pregnant uterine samples (n = 4)
were allowed to develop spontaneous contractions, with changes to contraction
characteristics monitored after the addition of either 1 nM OT, 0.1 µM PGF2a, 30 µM m3M3FBS, or 10 µM U73122 to the organ bath.
The effect on contraction frequency after addition of GPCR and PLCs agents was
variable (Figure 33A). No significant effects on frequency were found by addition of OT
(P = 0.875), PGF2a (P = 0.375), m-3M3FBS (P = 0.875), or U73122 (P = 0.5). Analysis
of amplitude changes demonstrated no significance with agents having the following
values: OT (P = 0.25), PGF2a (P = 0.375), m-3M3FBS (P = 0.375), U73122 (P = 0.5).
While not statistically significant, agents that increased internal calcium store release did
show a trend in increasing contraction amplitudes, as was expected due to increased
cytosolic calcium levels from multiple mechanisms (Figure 33B). Overall cumulative
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Figure 32. Summary of contractile results in the comparison of increasing CyPPA
concentration with or without CPA pretreatment. Control and CPA treated nonpregnant (n = 9) and pregnant (n = 10) uterine samples were compared for changes in
contraction frequency (A, B), amplitude (C, D), and AUC (E, F). Data were normalized
to either control contractions or CPA stimulated contractions for comparison between the
treatment groups. Box plot of medians with minimum and maximum values represented
by whisker bars. Data were analyzed by Wilcoxon matched-pairs rank test with false
discovery rate approach for multiple comparisons.
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changes in contractions, in the form of AUC, were not found to be significant for
OT (P = 0.625), PGF2a (P = 0.125), m-3M3FBS (P > 0.99), or U73122 (P > 0.99; Figure
33C).
Identifying baseline contraction changes by each GPCR or PLC agent allowed us
to assess further alterations by positive or negative KCa2.3 modulators. Spontaneously
contracting tissue were incubated with either 10 µM CyPPA (n = 9) or 0.5 µM
apamin (n = 9) for 20 minutes, with the addition of 1 nM OT, 0.1 µM PGF2a, 30 µM
m-3M3FBS, or 10 µM U73122 afterwards. Results of these studies continued to
demonstrate a variable response of pregnant tissue to CyPPA.
Myographical examples of these findings (Figure 34) show uterine samples from
the same pregnant patient having inconsistent response to 10 µM CyPPA. Both CyPPA
and apamin, in the presence of a GPCR or PLC agent, were compared to that agent’s
baseline functioning to assess the ability of KCa2.3 channel modulation to alter
contractions. Changes in frequency were analyzed and found to not be significant with
OT augmented contractions compared to CyPPA with OT (P > 0.99) and apamin with
OT (P > 0.99). Amplitude assessment of OT vs CyPPA with OT (P = 0.41) and OT vs
apamin with OT (P = 0.66) did not demonstrate significance and AUC results of OT vs
CyPPA with OT (P = 0.5) and OT vs apamin with OT (P > 0.99) were not significant
either (Figure 35).
CyPPA and apamin were not able to significantly alter PGF2a contraction
baseline frequency as P was > 0.99 for both PGF2a vs CyPPA with PGF2a and PGF2a vs
apamin with PGF2a. Baseline contraction amplitudes were also not significantly altered
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Figure 33. Alterations to spontaneous contractions of pregnant uterine tissue after
administration of GPCR or PLC agents. Graphical representation of changes in
contraction frequency (A), amplitude (B), and AUC (C) of pregnant uterine sample (n =
4) after the administration of either 1 nM OT, 0.1 µM PGF2a, 30 µM m-3M3FBS, or 10
µM U73122. Box plot of medians with minimum and maximum values represented by
whisker bars. Data were analyzed by Wilcoxon signed rank test.
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Figure 34. Myographical recordings of pregnant tissue samples from the same
subject incubated with CyPPA prior to administration of GPCR or PLC agents. The
uterine tissue sample in panel A has no observed response to 10 µM CyPPA, while the
waveform of the sample in panel B undergoes a morphological change. The sample in
Panel D has a slight increase in frequency and reduction of amplitude.
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Figure 35. Effects of oxytocin on pregnant uterine contractions in presence of
KCa2.3 channel modulators. Pregnant uterine samples (n = 9) pretreated with OT (1
nM) were exposed to KCa2.3 channel positive modulator, CyPPA (10 µM) or KCa2.3
channel negative modulator, apamin (0.5 µM). Alterations to contraction frequency (A),
amplitude (B), and AUC (C) were analyzed. Box plot of medians with minimum and
maximum values represented by whisker bars. Data were analyzed by Kruskal-Wallis
test.
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Figure 36. Effects of prostaglandin F2a on pregnant uterine contractions in presence
of KCa2.3 channel modulators. Pregnant uterine samples (n = 9) pretreated with PGF2a
(0.1 µM) were exposed to KCa2.3 channel positive modulator, CyPPA (10 µM) or
KCa2.3 channel negative modulator, apamin (0.5 µM). Alterations to contraction
frequency (A), amplitude (B), and AUC (C) were analyzed. Box plot of medians with
minimum and maximum values represented by whisker bars. Data were analyzed by
Kruskal-Wallis test.
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Figure 37. Effects of m-3M3FBS on pregnant uterine contractions in presence of
KCa2.3 channel modulators. Pregnant uterine samples (n = 9) pretreated with m3M3FBS (30 µM) were exposed to KCa2.3 channel positive modulator, CyPPA (10 µM)
or KCa2.3 channel negative modulator, apamin (0.5 µM). Alterations to contraction
frequency (A), amplitude (B), and AUC (C) were analyzed. Box plot of medians with
minimum and maximum values represented by whisker bars. Data were analyzed by
Kruskal-Wallis test.
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as PGF2a vs CyPPA with PGF2a incurred a P > 0.99 and PGF2a vs apamin with PGF2a
ended with a P = 0.99. Collective assessment of contractility via AUC values revealed
neither PGF2a vs CyPPA with PGF2a (P = 0.98) or PGF2a vs apamin with PGF2a (P =
0.22) meeting statistical significance (Figure 36).
Outcomes of KCa2.3 channel modulation were assessed with the PLC activator
m-3M3FBS. Frequency results of m-3M3FBS vs CyPPA with m-3M3FBS (P = 0.38) and
m-3M3FBS vs apamin with m-3M3FBS (P = 0.71) proved to not be significant, as was
the case for amplitude results: m-3M3FBS vs CyPPA with m-3M3FBS (P = 0.78), m3M3FBS vs apamin with m-3M3FBS (P > 0.99). Neither KCa modulator was able to
significantly alter the AUC baseline, with m-3M3FBS vs CyPPA with m-3M3FBS
earning a P = 0.7824, and m-3M3FBS vs apamin with m-3M3FBS at a P = 0.88 (Figure
37).
U73122 was the lone antagonist to internal calcium store release tested in this arm
of the project. As a decrease of internal store release would reduce the activation of the
KCa2.3 negative feedback system, it was postulated U73122 would increase contractility
in the presence of CyPPA. When the KCa2.3 hyperpolarizing effect is inhibited via
apamin, decreased store calcium release was theorized to reduce contractility. CyPPA
with U73122 did not significantly alter frequency (P > 0.990, amplitude (P > 0.99), or
AUC (P > 0.99) when compared to U73122 alone. This lack of significance was also true
for apamin, as apamin with U73122 was unable to significantly change frequency (P =
0.52), amplitude (P > 0.99), or AUC (P = 0.78), compared to U73122 augmented
contractions (Figure 38).
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Figure 38. Effects of U73122 on pregnant uterine contractions in presence of KCa2.3
channel modulators. Pregnant uterine samples (n = 9) pretreated with U73122 (10 µM)
were exposed to KCa2.3 channel positive modulator, CyPPA (10 µM) or KCa2.3 channel
negative modulator, apamin (0.5 µM). Alterations to contraction frequency (A),
amplitude (B), and AUC (C) were analyzed. Box plot of medians with minimum and
maximum values represented by whisker bars. Data were analyzed by Kruskal-Wallis
test.
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Apamin as a pro-contractile agent was not supported through statistical analysis,
or graphical representation, as myographical representations of apamin effects on
contractions ranged from observed minimal amplification to relaxation (Figure 39).

Figure 39. Myographical recordings of pregnant tissue incubated with apamin prior
to administration of GPCR or PLC agents. Apamin, which recovers CyPPA
augmented contractions through KCa2.3 pore blocking effects, showed variable effects
on pregnant tissue. Reductions in amplitudes were observed in panels A and C, with
frequency decreasing in panel A, B, and D, and increasing in panel C.
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CHAPTER V
DISCUSSION

Myometrial studies in mouse, rat, and human tissues have proposed a role of
KCa2.3 channels in the negative feedback control of uterine contractions. The purpose of
this project was to assess the impacts of different sources of calcium sources for
activation of KCa2.3 channels. This was performed by characterizing the effects of
internal calcium store modulation on contractions and evaluating the potential
relationship between internal calcium stores and KCa2.3 channels. To achieve this, it was
necessary to characterize spontaneous contractions of non-pregnant and pregnant human
uterine tissue, determine the ability of CyPPA to inhibit gestationally different human
uterine contractions, and examine CyPPA efficacy in the presence of amplified and
diminished internal calcium store release.
KCa2.3 channels were first identified as a potential regulator in myometrial
contractibility when Bond et al. observed that mice who conditionally overexpressed
KCa2.3 channels (SK3T/T) had protracted delivery.12 Further studies in mice by Brown et
al. identified that the KCa2.3 channels were present in myometrial tissue21 and Pierce et
al. reported KCa2.3 channel expression in whole uterine samples decreased over the
course of gestation 22 with Skarra et al. recognizing a gestational decrease in murine
KCa2.3 channel expression in myometrial samples.27 Noble et al. determined KCa2.3
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channel expression was not statistically different between non-pregnant and pregnant
samples, which provides some evidence of species dependent channel differences.18
Human uterine assessment by Mazzone et al. revealed a down-regulation of KCa2.3
transcript in pregnant myometrium versus non-pregnant myometrium.87,97 Rahbek et al.
confirmed that KCa2.3 mRNA and protein levels were significantly lower in the
myometrium from pregnant women compared to the non-pregnant group.19 This trend
was observed both in the preterm and term group, as well as non-laboring and laboring
group.19

Expression and distribution of KCa2.3 and IP3R channels in human myometrium
Immunofluorescent studies with mouse myometrial samples by Skarra et al.
found that KCa2.3 channels were highly concentrated along the cell periphery, consistent
with predominant membrane localization and no obvious changes in cellular distribution
over the course of gestation were visualized.27 Previous double immunofluorescent
labeling experiments in human uterine tissue used KCa2.3 and CD34 (smooth muscle)
antibodies.23 These studies found KCa2.3 expression in telocytes, which are interstitial
Cajal-like cells, of non-pregnant human myometrium but not in smooth muscle cells.23 In
pregnant human myometrium, staining for KCa2.3 channels was not present in smooth
muscle cells or telocytes. No further information or gestational changes regarding
KCa2.3 location or distribution were discussed.23
Our findings differed from the previous study in that we found KCa2.3 expression
throughout the myometrium with signal appearing to be in the muscle fibers due to the
orientation of the signal and location relative to nuclei. It was difficult to visually
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compare KCa2.3 expression levels between non-pregnant and pregnant as the signal was
present throughout both tissue groups. More interestingly to discuss was the assortment
of distribution patterns observed in the tissue; with all the variety it was not hard to
speculate that tissues would respond differently. Cellular architecture is a concept that
explains channel function through the components of channel expression and cellular
distribution. Protein expression studies provide information on overall channel protein
levels but does not answer if the channel is functional A study could find that channel
expression is high, but those channels could be in vesicles and not be in a position to have
an effect. Specifically, with KCa channels, their proximity to a calcium source for
activation has more functional value then their population. A few well-placed KCa
channels next to a preferential source of calcium (VGCC, IP3R, TRP) could create
enough repolarizing influence to trigger relaxation. On the opposite end, many KCa
channels in an area without a calcium source channel requires the channels to rely on
global calcium levels potential leading to a reduced repolarizing effect. The variability of
channel arrangements, paired with the variability of tissue function, supports the concept
that the cellular functional architecture determines the contractile properties of the tissue.
As KCa channels are often located near calcium sources we assessed the potential
for co-localization of KCa2.3 and IP3R channels with dual immunofluorescent staining.
Some samples showed very distinct individual channel signal with little co-expression,
while other samples displayed small puncta or larger tracts of co-expression. Similar
patterns of punctated clusters and densities were found with immunofluorescent studies
of IP3R channels in swine coronary arterial endothelium.34 All the functional
inconsistencies found in this study supports this variety of proximity staining and
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warrants further investigation into this potential coupling with higher power
magnification studies and proximity assessments.
The primary KCa2.3 antibody used in the dual staining protocol is one our
laboratory has vetted and used in a variety of tissues, but the IP3R primary antibody is
newer to our laboratory. Dual staining is known to have its difficulties and early in this
project only rabbit primary antibodies were available. Dual staining with two rabbit
primary antibodies resulted in a large amount of costaining where individual channels
were not able to be distinguished. Primary antibodies from different species became
available and allowed us to see distinct signals with lower amounts of costaining. We
also tested our dual staining protocol on other tissues and while these antibodies are still
being optimized, dual staining studies are resulting in clearer images.

Spontaneous and augmented contractions of human uterine tissue

Characteristics of spontaneous contractions
Few studies were found in the literature characterizing spontaneous contractions
amongst non-pregnant and pregnant human subjects, with most having lower n values. To
better understand the start-point for performed studies, characterization of spontaneous
contractions was necessary. Variation in frequency and amplitude of spontaneous
contractions were observed, which created a vast scatter and spread of results. Agerelated studies by Arrowsmith et al. demonstrated that AUC of non-pregnant and
pregnant spontaneous contractions had much scatter as well. Further data subset analysis
by their group controlled for parity, gestational age, mother’s BMI, baby’s birthweight,
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and only a previous cesarean section as an indication for surgery, did not change the data
spread.165 This study did not compare contraction characteristics between non-pregnant
and pregnant tissue directly.
Arrowsmith et al. evaluated pregnant spontaneous contractions of term and
postdate women (total n = 58) and found mean contraction frequency to be 1.14 for term
women and 1.87 for postdate women. Mean contraction amplitude was 3.6 mN for term
pregnant women and 2.07 mN for postdate pregnant women.166 These values correlate
with our findings for frequency and amplitude of pregnant contractions. Rosenbaum et al.
compared human myometrial contractions of non-pregnant and pregnant women and
found amplitude, time between contractions, and AUC were significantly greater in
pregnant samples.167 Raw data from their study is very different to what we collected, as
their mean amplitude of non-pregnant tissue was 6.53 mN and 11.33 mN for pregnant
tissue. Study differences include our use of uterine rings rather than strips and sample
size. We used replicate samples, 109 samples from 18 non-pregnant women and 159
samples from 19 pregnant women. Their n of 9 referred to the number of patients and it
was assumed this was the total number of samples as they did not list otherwise.
Additional study methods were similar and reasons for the difference is unclear.
The variation of contractile features and myographical waveforms of separate
samples from the same patient, could be explained by disruption of the electrochemical
syncytium. The method for preparation of myometrial samples results in samples that are
not structurally uniform as amount of contractile tissue and orientation of muscle fibers
between samples is not always the same. Immunofluorescence of myometrial samples
identified distinct smooth muscle bands and confirmed their varied orientation. Should
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the mean vector of force for a sample not align with the transducer pins, quantities of
each contraction are not accounted for. One study found only 65% of the cross-sectional
area of myometrial strips is contractile tissue168 and another study suggested 85-90% of
uterine myocytes are oriented perpendicular to the axis of the strip.169 It is most likely
that through sample dissection the orientation of muscle fibers and force vectors were
compromised, leading to greater variability in spontaneous contractions. In order to
create structurally uniform samples, we should aim to capture muscle fibers traveling in
an orientation that is the same amongst samples and fully assessed by equipment, which
is likely difficult. The force vector of non-pregnant tissue could be inferred due to the
orientation of fibers, but unlikely in pregnant samples as the fibers became increasingly
interwoven. Even with the identification of the force vector for an individual sample, the
mean vector for the organ itself cannot be inferred due to the small section of tissue
studied. Sampling of a small section of myometrial tissue was not reflective of the overall
coordinative effects of the organ, especially in pregnant samples.
Rather than one pacemaker cell being dominant for a given region of tissue,
dissection of the tissue into smaller strips causes new pacemakers to control the rate of
action potential firing. When individual strips are regulated by different pacemakers, a
variety of waveforms with variable characteristics are generated. Samples from pregnant
patients had an increased rate of not developing contractions when compared to nonpregnant samples (18.98% vs 3.85%). As myocytes hypertrophy during pregnancy, using
the same sample size between gestational groups may have led to a pacemaker cell not
being captured in samples.
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Based on gestational changes such as downregulation of KCa2.3 channels,
increased gap junction formation, and upregulation of contraction-associated proteins, it
was theorized that contraction amplitude would be greater in pregnant samples. Overall
pregnant samples had smaller values for frequency and amplitude compared to nonpregnant samples, which was surprising. The frequency and amplitude distribution
between gestational groups was also unanticipated, as we expected the shape of the
histogram to remain generally similar, even if median values shifted. Instead, the
histograms in pregnant samples were more right skewed than non-pregnant samples for
contraction indices.
Smaller values for frequency and amplitude could be explained by the overall
objective of a pregnant uterus. During labor the uterus does not attempt to create the
largest contraction possible, but rather to coordinate myocyte activity into organ level
involvement and provide deliberate movement of the fetus. Increased gap junctions and
membrane potential reduction are two gestational adaptations with the goal of triggering
an action potential that will propagate and recruit all uterine regions in a top-down
fashion for effective delivery of the fetus. Based on this goal for contraction
synchronization rather than magnitude, smaller amplitudes may be an appropriate and
physiologic change during labor. Additional reasons for gestational differences could be
due to maternal age as other groups found that older pregnant mothers had decreased
contraction amplitude when compared to younger pregnant mothers.165 Retrospective
analysis with segregation of laboring vs non-laboring and maternal age, may demonstrate
a trend in spontaneous contractions between subgroups.
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Myometrial contractile proteins may be another potential reason for lower
amplitudes in pregnant women. During pregnancy there is increased expression of
smooth muscle myosin, but due to increase in myocyte cell size, the amount of myosin
per milligram of protein is maintained compared to a non-pregnant state.169 Caldesmon, a
smooth muscle thin-filament-associated protein that inhibits generation of force by
myosin, increases 4-fold in pregnant myometrium. A disproportionate increase in
caldesmon expression relative to myosin during pregnancy may cause an inhibition of
contractile force prior to initiation of labor.170 Most of the pregnant study participants
were non-laboring and therefore the activation of contraction-associated proteins and
physiologic amplification of contractions may not have occurred.
CyPPA diminishes contractions in non-pregnant and pregnant human myometrium
Skarra et al. identified that increasing concentrations of CyPPA did not have a
significant effect on spontaneous contraction frequency in non-pregnant, mid-pregnant
and term pregnant mice.27 Amplitudes for these contractions were suppressed in a dosedependent fashion and could be recovered by apamin. CyPPA responses were also right
shifted in mid-and term pregnancies compared to non-pregnant mouse samples,
indicating reduced CyPPA sensitivity with pregnancy.27
The only known human myometrial study utilizing CyPPA was conducted by
Rosenbaum et al. who evaluated cumulative CyPPA concentrations (0.1 – 60 uM) in nonpregnant (n = 6) and pregnant (n = 6) patient samples. A concentration-dependent
reduction of contractility was recorded, with 60 µM of CyPPA completely abolishing
contractions. They assessed percentage of relaxation as a function of the integral (AUC)
and did not evaluate frequency or amplitude changes.26
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This study is the first to assess individual contributions to contractions by
evaluating frequency and amplitude, as components of overall contractility. We observed
that individual non-pregnant and pregnant samples had variable responses to CyPPA.
After plotting the progression of each sample through increasing concentrations of
CyPPA it was noted that some samples had increases in frequency or amplitude over the
treatment course. Other samples seemed to be unresponsive to CyPPA. Despite these
inconsistencies we found significant reductions in contraction frequency, amplitude, and
AUC through the course of treatment. Generally, all contractile components were
reduced after 30 µM CyPPA (highest concentration assessed), with varying significance
amongst other concentration interactions. We are the first to compare CyPPA
effectiveness between non-pregnant and pregnant human myometrial samples. CyPPA
demonstrated similar effects on contraction frequency and AUC between the gestational
groups and CyPPA reduced contraction amplitude in the pregnant samples more than the
non-pregnant samples. These results indicate that CyPPA has greater effects on
diminishing contraction amplitude in human pregnant samples, but not to the point that it
significantly reduces overall contractility.
Reasons for variability amongst pregnant tissue samples response to CyPPA could
be due to differences in KCa2.3 location and distribution. Previous studies looked at
KCa2.3 channel expression values and found human uterine channel levels decrease in
late gestation.20 These studies only look at the protein expression and not the location or
distribution patterns, which we evaluated. Immunofluorescent staining of non-pregnant
and pregnant tissue samples demonstrated multiple patterns of KCa2.3 expression and
distribution. Some samples had a very diffuse pattern of KCa2.3 staining while others
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had regions of pronounced puncta or clustered densities. The assortment of
immunofluorescent patterns would prompt me to theorize CyPPA would have varied
effects. Differences in the functional architecture could alter the CyPPA response of a
given tissue. The number of channels may not be as important as a channel’s proximity to
a calcium source. A few KCa2.3 channels clustered around a VGCC or IP3R channel can
preferentially be activated thereby increasing channel kinetics compared to widely
distributed KCa2.3 channels without a close source of activation calcium. Samples with a
stronger response to CyPPA could have one type of KCa2.3 expression pattern while
samples that appeared unresponsive may have another type of channel expression pattern.
Gestational age of pregnant tissue could lead to inconsistent CyPPA response
amongst tissue samples. Term pregnant samples were the largest sub-group within
pregnant samples and their gestational age range was approximately four weeks.
Parturition based hormone levels can begin to increase or decrease within a week, which
may alter KCa2.3 expression levels and potentially distribution patterns. Progesterone has
not been found to alter KCa2.3 expression19 but estrogen has. Two specificity protein
transcription factors that are expressed in the uterus compete to regulate KCa2.3 channel
expression during pregnancy in response to stimulation by estrogen.171 Week or more
differences in gestational age could lead to altered KCa2.3 expression and therefore
CyPPA response.
Non-pregnant samples were excised from uteri that were being removed due to
confounding clinical manifestations. All the non-pregnant samples had a diseased state
that could be altering multiple contractile properties. Care was taken to not sample from
grossly abnormal tissue, but changes that were not observed via stereomicroscope are
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likely. KCa2.3 expression patterns in diseased uterine tissue has not been studied, but
uterine fibroids and endometriosis can alter expression of varying contractile proteins and
lead to changes in contractility if these samples were hypothetically compared to nondiseased non-pregnant tissue.
Utilizing already obtained data, further studies can correlate functional data to
expression and distribution patterns to evaluate for potential trends. By comparing the
type of channels staining pattern to tissue CyPPA response we can investigate if
CyPPA’s effect depends on KCa2.3 distribution. Being able to predict expression pattern
based on functional data or vice versa, could allow future studies to sub-type tissue to
better compare similar samples. Correlation studies can also extend into the clinical
patient history. Detecting pairings of clinical features, such as underlying uterine
pathology, gestational age, maternal age, and number of previous deliveries, and
functional or imaging characteristics could allow investigators to stratify patients into
appropriate groups for comparisons. Additionally continuing to collect pregnant tissue in
attempts to increase the number of preterm delivery samples could evaluate CyPPA
effectiveness between preterm and term pregnancies to further strengthen evidence of
CyPPA as a potential tocolytic.

Internal calcium stores and KCa2.3 modulation of human myometrial contractility

Human myometrial contractility after CyPPA and oxytocin treatment
Oxytocin receptors increase during late gestations allowing serum oxytocin levels
to amplify contractions during labor. For a tocolytic medication to be effective it must be
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able to maintain relaxation effects in the presence of physiologic contractile agents,
therefore effects of contractions in the presence of oxytocin and CyPPA were evaluated.
Skarra et al. found that application of CyPPA caused concentration-dependent decreases
in contraction amplitude of non-pregnant and pregnant murine samples. Pretreatment
with oxytocin did not significantly reduce CyPPA maximal effect in non-pregnant or
pregnant samples, with CyPPA sensitivity reduced in pregnant samples.27
In this study oxytocin administration led to tissue sample waveform changes that
altered contraction frequency, amplitude, and sometimes both. Due to oxytocin’s multiple
mechanisms, these waveform shifts were expected. Oxytocin increases calcium influx
through membrane channels, triggers internal calcium store release through IP3
generation, and reduces the efflux of calcium from the cytoplasm, which can all lead to
contractile changes. We expected some variability in sample response to oxytocin, based
on clinical findings of inconsistent patient responses to oxytocin when it was
administered for the initiation/stimulation of labor, but the degree of variability was
unanticipated.172–174 Multiple calcium-based pathways are affected by oxytocin binding,
creating an interdependent network of signals that can play a role in regulating
contractions. Altering the functionality, expression levels, or location of OTRs can affect
channel kinetics of membrane potassium channels and IP3R therefore modifying
downstream effects. We did not stain for OTR expression or distribution in human
myometrium, which should be included in a follow up project, but based on the variance
of KCa2.3, and to a lesser extent IP3R, we can postulate that OTR distribution will also
be variable. In deciphering a samples response to oxytocin, we looked for a waveform
change as some samples seemed unresponsive to oxytocin, and if a waveform change
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occurred what aspect of contractions changed; the frequency, amplitude, or both. As
relationships between cellular elements are being assessed the inherent variability within
each element’s arrangement in the cell and then their organization in relation to one
another, creates greater potential for functional difference. Samples displayed an array of
functional changes to oxytocin which we theorize is due to the underlying cellular
architecture determining the specificity of response.
As previously discussed, the stage of pregnancy or labor may be affecting cellular
architecture and response to agents due to shifts in gestational hormones. Preterm and
term patients in a non-laboring situation may be in a transitional or transformative stage
where functional relationships required for contraction coordination and synchronization
have not matured. Estrogen levels regulate OTR expression levels which could result in
non-laboring tissue having fewer functional OTRs and a reduced IP3R activation.
Previous deliveries or underlying maternal conditions could also have an impact on tissue
response to oxytocin through previous changes to uterine structure or chronic
inflammatory conditions. Correlation studies comparing laboring tissue to non-laboring
tissue in oxytocin response and KCa2.3 distribution pattens may uncover a pattern of
response consistent with gestational age or laboring status. Further studies expanding on
this idea and incorporating OTR expression and distribution analysis via
immunofluorescence, could provide more information on the ability of cellular
arrangement to effect tissue function.
Oxytocin was employed to investigate the relationship between increased internal
store release and the relaxing effects of KCa2.3 positive modulation. We investigated
what oxytocin did in the presence of CyPPA, whether oxytocin boosted contractility
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through increased cytosolic calcium mechanisms or if CyPPA prevented oxytocin’s procontractile mechanisms. There was also the potential for preferential activation of
KCa2.3 channels by IP3R-mediated calcium release, which has been found between IP3R
and TRP channels130,132,133,136, BKCa channels126,127, and IKCa channels32,34,35. In this
portion of the project, we found that oxytocin was not able to overcome contractions
previously diminished by CyPPA. CyPPA could still significantly reduce contractility in
the presence of oxytocin, and the order in which these agents were added did not alter
outcomes. These findings support that amplifying the innate KCa2.3 negative feedback
mechanism with CyPPA, creates an environment where oxytocin’s effects are truncated.
Increasing the calcium sensitivity of KCa2.3 turns on repolarization effects at lower
cytosolic calcium levels and shuts down VGCC earlier in a contraction cycle. Decreasing
the open time of VGCC reduces calcium influx and intracellular calcium levels, limiting
the potential for activation of contractile machinery. Based on our findings, the procontractile mechanisms of oxytocin are not enough to overcome these effects. In some
samples there was a greater reduction in contractility with increasing concentrations of
oxytocin suggesting that in tissue with a certain structural arrangement, oxytocin may
promote the relaxing effects of CyPPA by promoting release of internal calcium stores in
close proximity to KCa2.3 channels, further amplifying the feedback response.
Additional studies are needed to evaluate the staining patterns of OTRs in tissue and
potentially location relative to other channels to determine if this functional architecture
is at the heart of these findings.
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Alterations to CyPPA augmented contractions after internal store depletion
To determine if CyPA is still effective with internal stores depleted, we assessed
contraction changes after SERCA blockade in non-pregnant and pregnant uterine
samples. Addition of CPA led to changes in waveform morphology in both gestational
groups. These changes were not always consistent but commonly there was an increase in
frequency, and reduction in amplitude and development of some baseline tone. Tone is
not associated with contractions per se, but rather intracellular calcium concentrations.
Initially after addition of CPA and inhibition of the SERCA pump, there is an increase in
global calcium levels, potentially explaining the development of tone and waveform
changes. As no calcium reuptake is occurring, store operated channels sense low store
levels and open for calcium influx, further increasing global calcium levels. Eventually
the increased calcium will leave the cell via efflux channels, cytosolic calcium levels will
return to normal and internal stores will be depleted. Any contraction after this point will
be without the assistance of internal stores. Additional studies quantifying the tone
created by CPA could shed further light on the internal store contributions.
Depleting the internal stores did not hamper CyPPAs ability to dimmish uterine
contractions, suggesting that in an unstimulated state, internal stores are not a main
contributor to KCa2.3 activation. CyPPAs capabilities in a stimulated state via
prostaglandins or oxytocin could be evaluated in the future to further categorize the role
of the internal stores in the KCa2.3 negative feedback mechanism.
CPA was chosen for its ability to deplete internal stores, but the initial goal of this
project section was to block the IP3R channel. Unfortunately, because available
pharmacologic inhibitors and modulators of IP3Rs are notoriously non-selective with
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many off target effects, we were not able to precisely address IP3R functional role. Since
we could not block the IP3R directly, we had to adjust the function of IP3R by
controlling up and down stream regulators. Additional studies using siRNA, genetic or
antibody approaches could be used to directly assess IP3 effects of KCa2.3 feedback.
Effects of increased internal calcium release on spontaneous and KCa2.3 modulated
human myometrial contractions
Continuing with the hypothesis that increased internal store release would
preferentially activate KCa2.3 channels and amplify the channels negative feedback
mechanism, multiple agents that modified IP3 generation were assessed. These results
were also an opportunity to assess two new agents, m-3M3FBS and U73122, that have
never been studied in human myometrial tissue. First an assessment of the baseline
effects these agents (OT, PGF2a, m-3M3FBS, U73122) have on spontaneous
contractions were performed. There were no significant findings for this section of the
study, but this section had the smallest sample size (n = 4). Due to the variability of
contractions noted throughout this entire project, a n of 4 may not have been enough to
gain significance. Future studies could continue to evaluate these new agents in a larger
scale format. Of note Padal et al. evaluated m-3M3FBS in a high cholesterol pregnant
murine model to demonstrate any effect on high cholesterol diet on the phospholipase C
pathway. m-3M3FBS was added cumulatively (0 – 50 µM) to mouse uterine strips and it
produced a concentration-related relaxation that was not statistically significant.175
Once expected alterations to contractions by the GPCR and PLC agents were
established, additional studies looked at potential deviation from baseline with positive or
negative modulation of KCa2.3 channels. Results of these studies continued to
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demonstrate a variable response of pregnant tissue to CyPPA and apamin. While not
significant, CyPPA’s trend of relaxation compared to internal store agonists baseline, did
align with initial hypotheses, if not due to cooperation between internal stores and
KCa2.3 channels, then the amplification of KCa activity and subsequent
hyperpolarization. Apamin has been shown to recover CyPPA diminished contractions in
murine models27, increase rat myometrial contractility18 and have no significant effect on
human myometrium167. We theorized that KCa2.3 channel blockade in the presence of
augmented internal store release would have a pro-contractile effect due to the decrease
in repolarizing effects. Statistical analysis did not support this idea, nor did the trendlines,
as apamin with a GPCR or PLC agonist rarely had effects greater than the agent alone. A
lack of effect with KCa2.3 blockade is likely due to it not being the main component of
repolarization for myocytes. Potassium efflux is required for relaxation but there was
many other potassium channels that can continue with potassium efflux if KCa2.3 is
inhibited.
Further studies could begin to assess additional relationships between KCa2.3
channels and other channels that have regulatory effects on uterine contractility. Interesting
studies have identified the TRPV family as potential modulators of contractions and a
relationship between TRPV channels and KCa2 channels in the uterus may yield
fascinating findings.

Conclusions
Human uterine contractions are different in every patient, not only within
gestational groups, but between them as well. Frequencies and amplitudes are not the
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same with distributions being more skewed in pregnant tissue. CyPPA relaxes uterine
tissue regardless of gestational state. These results were significant across the board with
frequency, amplitude, and overall contractility, but individual responses varied in respect
to the magnitude of response. CyPPA was also more effective at decreasing contraction
amplitude in pregnant tissue. SERCA blockade and internal store depletion did not
hamper CyPPAs abilities to relax contractions but doing so caused waveform changes in
a number of samples identifying a potential role of internal stores. CyPPA not only blunts
oxytocin's pro-contractile response but can significantly diminish pregnant myometrial
contractions in its presence.
Findings from this project have shown many areas of variability with human
myometrial tissue, which I perceive to be caused by the differences in cellular
architecture noted on immunofluorescence. The expression and distribution patterns of
regulating channels are going to lead to functional changes, and with the variety of
staining patterns that were visualized amongst and between non-pregnant and pregnant
groups, the functional differences aren’t that surprising.
A big question surrounding this study was: are pieces of tissue predictive of the
whole organ? Based on the underlying goal of a pregnant uterus to synchronize and
coordinate contractions to effectively move the fetus, I do not foresee tissue samples
being representative of the whole organ. Currently we do not have methods to safely
assess contractile components of an entire uterus therefore we must work with the
variability compounded by tissue sample creation and innate differences in cellular
architecture amongst patients.
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Investigators can work with the variability and further separate gestational states
into smaller sub-groups and study those accordingly, because non-pregnant and pregnant
human myometrium are not the same. Prescreening uterine tissue for study inclusion
could involve assessing if samples functioning within median values, if so it can be
grouped with others like it for comparison. Outliers can be identified earlier, and either
excluded or grouped with like samples to be further assessed for changes in the
contractile apparatus.
Larger studies correlating cellular architecture to functional response can include
running parallel data from individual samples, to increase our knowledge on a tissue’s
functionality and a corresponding assessment of common channel expression.
Accumulation of this information may allow researchers to predict cellular arrangement
based on functional characteristics or vice versa. This type of information will help
stratify tissue into appropriate sub-groups for researchers to evaluate their scientific
questions more effectively.
Evaluation of other channels as possible pharmacological targets for tocolytic
agents can prove beneficial to many patients. Based on the variability noted in this study,
it is likely a single medication is not going to be the most effective treatment for preterm
labor. Multiple agents, each with a distinct and targeted myometrial response, could be
used together, to create a more effective tocolytic.
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APPENDICES

Appendix A: Supplementary figures

Figure 40. Secondary antibody only controls. Samples stained with only the secondary
antibody for KCa2.3 channels (A; Alexa Fluor 568) and IP3R channels (B; Alexa Fluor
488) demonstrated no fluorescent signal.
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Figure 41. Concentration-response curves for oxytocin, PGF2a, m-3M3FBS, and
U73122. Increasing concentrations of oxytocin (A), PGF2a (B), m-3M3FBS (C), and
U73122 (D) were added to spontaneously contracting non-pregnant tissue. Nonlinear
regression with best first curve was used to demonstrate tissue response as a percentage
of maximum AUC.

127

Appendix B: IRB approval certificate for hysterectomy studies
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Appendix C: IRB approval certificate for cesarean studies
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